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Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve the
effectiveness of care, optimize patient outcomes, and impact
the overall cost of care favorably by focusing resources on the
most effective strategies.
The American College of Cardiology (ACC) and the Amer-
ican Heart Association (AHA) have jointly engaged in the
production of such guidelines in the area of cardiovascular
disease since 1980. This effort is directed by the ACC/AHA
Task Force on Practice Guidelines, whose charge is to develop
and revise practice guidelines for important cardiovascular
diseases and procedures. Experts in the subject under
consideration are selected from both organizations to exam-
ine subject-specific data and write guidelines. The process
includes additional representatives from other medical prac-
titioner and specialty groups where appropriate. Writing
groups are specifically charged to perform a formal litera-
ture review, weigh the strength of evidence for or against a
particular treatment or procedure, and include estimates of
expected health outcomes when data exist. Patient-specific
modifiers, comorbidities, and issues of patient preference
that might influence the choice of particular tests or thera-
pies are considered as well as frequency of follow-up and
cost-effectiveness.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual or potential conflicts of interest
that might arise as a result of an outside relationship or
personal interest of a member of the writing panel. Specifically
all members of the writing panel are asked to provide disclo-
sure statements of all such relationships that might be per-
ceived as real or potential conflicts of interest. These state-
ments are reviewed by the parent task force, reported orally to
all members of the writing panel at the first meeting, and
updated yearly and as changes occur.
These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of generally
acceptable approaches for the diagnosis, management, or
prevention of specific diseases or conditions. These guidelines
attempt to define practices that meet the needs of most
patients in most circumstances. The ultimate judgment regard-
ing care of a particular patient must be made by the physician
and patient in light of all of the circumstances presented by
that patient.
The executive summary and recommendations are pub-
lished in the July 1 issue of Circulation. The full text is
published in Journal of the American College of Cardiology.
Reprints of the full text and the executive summary are
available from both organizations.
These guidelines have been officially endorsed by the
American College of Sports Medicine, the American Society
of Echocardiography and the American Society of Nuclear
Cardiology.
James L. Ritchie, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines
I. Introduction
The American College of Cardiology/American Heart As-
sociation Task Force on Practice Guidelines was formed to
make recommendations regarding the appropriate use of
testing in the diagnosis and treatment of patients with known or
suspected cardiovascular disease. Exercise testing is widely avail-
able and relatively low cost. For the purposes of this document,
exercise testing is a cardiovascular stress test using treadmill or
bicycle exercise and electrocardiographic and blood pressure
monitoring. Pharmacological stress and the use of imaging mo-
dalities (radionuclide imaging, echocardiography) are beyond the
scope of these guidelines.
The current committee was given the task of reviewing and
revising the guidelines for exercise testing published in Sep-
tember 1986. Since that report, many new studies have been
published regarding the usefulness of exercise testing for
prediction of outcome in both symptomatic and asymptomatic
patients. The usefulness of oxygen consumption measurements
in association with exercise testing to identify patients who are
candidates for cardiac transplantation has been recognized.
The usefulness and cost-effectiveness of exercise testing has
been compared with more expensive imaging procedures in
selected patient subsets. All of these developments are consid-
ered in these guidelines.
In considering the use of exercise testing in individual
patients, the following factors are important:
1. The quality, expertise, and experience of the professional
and technical staff performing and interpreting the study
2. The sensitivity, specificity, and accuracy of the technique
3. The cost and accuracy of the technique as compared with
more expensive imaging procedures
4. The effect of positive or negative results on clinical decision
making
5. The potential psychological benefits of patient reassurance
The format of these guidelines includes a brief description
of exercise testing followed by a discussion of its usefulness in
specific clinical situations. Usefulness is considered for (1)
diagnosis; (2) severity of disease/risk assessment/prognosis in
patients with known or suspected chronic coronary artery disease
(CAD); (3) risk assessment of patients early after myocardial
infarction; (4) specific clinical populations identified by gender,
age, other cardiac disease, or prior coronary revascularization;
and (5) pediatric populations. The recommendations for partic-
ular situations are summarized in each section.
The committee reviewed and compiled all pertinent pub-
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lished reports (excluding abstracts) through a computerized
search of the English-language literature since 1975 and a
manual search of final articles. Specific attention was devoted
to identification and compilation of appropriate meta-analyses.
Detailed evidence tables were developed whenever necessary
using specific criteria detailed in the guidelines. The meta-
analyses and evidence tables were extensively reviewed by an
expert in methodologies. Inaccuracies and inconsistencies in
the original publications were identified and corrected when-
ever possible. The recommendations made are based primarily
on these published data. Because there are essentially no
randomized trials assessing health outcomes for diagnostic
tests, the committee has not ranked the available scientific
evidence in an A, B, or C fashion (as was done in other
ACC/AHA documents). When few or no data exist, this is
noted in the text, and the recommendations are based on the
expert consensus of the committee.
The ACC/AHA classifications I, II, and III are used to
summarize indications as follows:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or treatment
is useful and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/
efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not
useful/effective and in some cases may be harmful.
A complete list of the hundreds of publications covering
many decades of exercise testing is beyond the scope of these
guidelines, and only selected references are included. The
committee consisted of acknowledged experts in exercise test-
ing, as well as general cardiologists, a general internist, a family
medicine physician, and cardiologists with expertise in the use
of stress imaging modalities. The committee included repre-
sentatives of the American Academy of Family Physicians, the
American College of Sports Medicine, and the American
College of Physicians. Both the academic and private practice
sectors, as well as both adult and pediatric expertise, were
represented. This document was reviewed by three outside
reviewers nominated by the ACC and by three outside review-
ers nominated by the AHA, as well as by outside reviewers
nominated by the American Academy of Family Physicians,
the American College of Physicians, the American College of
Sports Medicine, the American Society of Echocardiography,
and the American Society of Nuclear Cardiology. This docu-
ment will be reviewed 2 years after publication and yearly
thereafter by the task force to determine whether a revision is
needed. These guidelines will be considered current unless the
task force revises or withdraws them from distribution.
This report overlaps with several previously published
ACC/AHA guidelines for patient treatment that potentially
involve exercise testing, including guidelines for perioperative
cardiovascular evaluation for noncardiac surgery,1 guidelines
for management of patients with acute myocardial infarction,2
guidelines for percutaneous transluminal coronary angio-
plasty,3 and guidelines and indications for coronary artery
bypass graft surgery.4 These guidelines are not intended to
include information previously covered in guidelines for the
use of noninvasive imaging modalities. This report does not
include a discussion of radionuclide angiography, myocardial
perfusion imaging, or positron emission tomography, which are
covered in the recently published guidelines for clinical use of
cardiac radionuclide imaging.5 This report also does not in-
clude any discussion of stress echocardiography, which is
covered in the recently published guidelines for clinical appli-
cation of echocardiography.6 For clarity, there are occasional
references to the use of both radionuclide and echocardio-
graphic imaging techniques. However, these brief references
are not intended to provide a comprehensive understanding of
the use of these imaging modalities. For such an understand-
ing, the reader is referred to the other published guidelines.
These guidelines do apply to both adults and children.
Exercise Testing Procedure
General Overview Exercise testing is a well-established
procedure that has been in widespread clinical use for many
decades. It is beyond the scope of this document to provide a
detailed “how-to” description of this procedure. Such a de-
scription is available in previous publications from the AHA,
including the statement on exercise standards,7 guidelines for
clinical exercise testing laboratories,8 and guidelines for exer-
cise testing in the pediatric age group,9 to which interested
readers are referred. This section is intended to provide a brief
overview of the exercise testing procedure.
Indications and Safety Although exercise testing is gener-
ally a safe procedure, both myocardial infarction and death
have been reported and can be expected to occur at a rate of
up to 1 per 2500 tests.10 Good clinical judgment should
therefore be used in deciding which patients should undergo
exercise testing. Absolute and relative contraindications to
exercise testing are summarized in Table 1.
Exercise testing should be supervised by an appropriately
trained physician. As indicated in the ACP/ACC/AHA task
force statement on clinical competence in exercise testing,11
exercise testing in selected patients can be safely performed by
properly trained nurses, exercise physiologists, physical thera-
pists, or medical technicians working directly under the super-
vision of a physician, who should be in the immediate vicinity
and available for emergencies. The electrocardiogram, heart
rate, and blood pressure should be carefully monitored and
recorded during each stage of exercise as well as during
ST-segment abnormalities and chest pain. The patient should
be continuously monitored for transient rhythm disturbances,
ST-segment changes, and other electrocardiographic manifes-
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tations of myocardial ischemia. Further details are provided in
the AHA guidelines for clinical exercise testing laboratories.8
Equipment and Protocols Both treadmill and cycle er-
gometer devices are available for exercise testing. Although
cycle ergometers are generally less expensive, smaller, and less
noisy than treadmills and produce less motion of the upper
body, the fatigue of the quadriceps muscles in patients who are
not experienced cyclists is a major limitation, because subjects
usually stop before reaching their maximum oxygen uptake. As
a result, treadmills are much more commonly used in the
United States for exercise testing.
Commonly used treadmill protocols are summarized in a
variety of published documents. Although much of the pub-
lished data are based on the Bruce protocol, there are clear
advantages to customizing the protocol to the individual
patient to allow 6 to 12 minutes of exercise.12 Exercise capacity
should be reported in estimated metabolic equivalents (METs)
of exercise. If exercise capacity is also reported in minutes, the
nature of the protocol should be clearly specified.
Exercise End Points Although exercise testing is com-
monly terminated when subjects reach an arbitrary percentage
of predicted maximum heart rate, it should be recognized that
other end points (summarized in Table 2) are strongly pre-
ferred. There is a wide spectrum of individual subject values
around the regression line for maximum heart rate, which may
therefore be beyond the limit of some patients and submaximal
for others. The target heart rate approach has obvious addi-
tional limitations in patients receiving b-blockers, those with
heart rate impairment, or those with excessive heart rate
response. The use of rating of perceived exertion scales, such
as the Borg scale (see Appendix 1),13 is often helpful in
assessment of patient fatigue. Symptom-limited testing using
the Borg scale as an aid is very important when the test is used
to assess functional capacity. Rating of perceived exertion is
less helpful in pediatric populations.
Interpretation of the Exercise Test Interpretation of the
exercise test should include exercise capacity and clinical, hemo-
dynamic, and electrocardiographic response. The occurrence of
ischemic chest pain consistent with angina is important, particu-
larly if it forces termination of the test. Abnormalities in exercise
capacity, systolic blood pressure response to exercise, and heart
rate response to exercise are important findings. The most
important electrocardiographic findings are ST depression and
elevation. The most commonly used definition for a positive
exercise test result from an electrocardiographic standpoint is
greater than or equal to 1 mm of horizontal or downsloping
ST-segment depression or elevation for at least 60 to 80 millisec-
onds after the end of the QRS complex.4 The details of interpre-
tation are covered elsewhere in these guidelines.
Cost and Availability There are relatively few published
studies comparing the cost-effectiveness of treadmill exercise
testing with more expensive imaging procedures. Compared
with imaging procedures such as stress echocardiography,
stress single-photon emission computed tomography (SPECT)
myocardial perfusion imaging, and coronary angiography,
treadmill exercise testing can be performed at a much lower
Table 1. Contraindications to Exercise Testing
Absolute
● Acute myocardial infarction (within 2 d)
● Unstable angina not previously stabilized by medical therapy*
● Uncontrolled cardiac arrhythmias causing symptoms or hemodynamic
compromise
● Symptomatic severe aortic stenosis
● Uncontrolled symptomatic heart failure
● Acute pulmonary embolus or pulmonary infarction
● Acute myocarditis or pericarditis
● Acute aortic dissection
Relative†
● Left main coronary stenosis
● Moderate stenotic valvular heart disease
● Electrolyte abnormalities
● Severe arterial hypertension‡
● Tachyarrhythmias or bradyarrhythmias
● Hypertrophic cardiomyopathy and other forms of outflow tract obstruction
● Mental or physical impairment leading to inability to exercise adequately
● High-degree atrioventricular block
*Appropriate timing of testing depends on level of risk of unstable angina, as
defined by AHCPR Unstable Angina Guidelines.14 †Relative contraindications
can be superseded if the benefits of exercise outweigh the risks. ‡In the absence
of definitive evidence, the committee suggests systolic blood pressure of
.200 mm Hg and/or diastolic blood pressure of .110 mm Hg. Modified from
Fletcher et al.7
Table 2. Indications for Terminating Exercise Testing
Absolute indications
● Drop in systolic blood pressure of .10 mg Hg from baseline blood
pressure despite an increase in work load, when accompanied by other
evidence of ischemia
● Moderate to severe angina
● Increasing nervous system symptoms (eg, ataxia, dizziness, or near-
syncope)
● Signs of poor perfusion (cyanosis or pallor)
● Technical difficulties in monitoring ECG or systolic blood pressure
● Subject’s desire to stop
● Sustained ventricular tachycardia
● ST elevation ($1.0 mm) in leads without diagnostic Q-waves (other than
V1 or aVR)
Relative indications
● Drop in systolic blood pressure of $10 mm Hg from baseline blood
pressure despite an increase in workload, in the absence of other
evidence of ischemia
● ST or QRS changes such as excessive ST depression (.2 mm of
horizontal or downsloping ST-segment depression) or marked axis shift
● Arrhythmias other than sustained ventricular tachycardia, including
multifocal PVCs, triplets of PVCs, supraventricular tachycardia, heart
block, or bradyarrhythmias
● Fatigue, shortness of breath, wheezing, leg cramps, or claudication
● Development of bundle branch block or IVCD that cannot be
distinguished from ventricular tachycardia
● Increasing chest pain
● Hypertensive response*
*In the absence of definitive evidence, the committee suggests systolic blood
pressure of .250 mm Hg and/or a diastolic blood pressure of .115 mm Hg.
ECG indicates electrocardiogram; PVCs, premature ventricular contractions;
ICD, implantable cardioverter-defibrillator discharge; and IVCD, intraventricu-
lar conduction delay. Modified from Fletcher et al.7
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cost. Table 3 is a comparison of 1996 Medicare RVUs (relative
value units, professional and technical) for treadmill exercise
testing and selected imaging procedures. These RVUs provide
an estimate of relative costs. Compared with the treadmill
exercise test, the cost of stress echocardiography is at least 2.4
times higher, stress SPECT myocardial imaging 5.3 times
higher, and coronary angiography 20 times higher. Lower cost
of the treadmill exercise test alone does not necessarily result
in a lower overall cost of patient care, as the cost of additional
testing and interventions may be higher when the initial
treadmill exercise test is less accurate than these more sophis-
ticated procedures.
Treadmill exercise testing is performed frequently. As
shown in Table 3, treadmill exercise tests are performed about
as often as the most frequent imaging procedure (stress
SPECT myocardial perfusion imaging). An estimated two
thirds of the treadmill exercise tests charged to Medicare in
1994 were performed as office procedures, and 33% of the
charges were submitted by noncardiologists. Thus, treadmill
exercise tests are more widely performed, do not always
require a cardiologist, and are convenient for the patient
because they are often an office-based procedure.
Clinical Context The vast majority of treadmill exercise
testing is performed in adults with symptoms of known or
suspected ischemic heart disease. Special groups who repre-
sent exceptions to this norm are discussed in detail in sections
VI and VII. Sections II through IV reflect the variety of
patients and clinical decisions (so-called “nodal points”) for
which exercise testing is used. Although this document is not
intended to be a guideline for the management of stable chest
pain, the committee thought that it was important to provide
an overall context for the use of exercise testing to facilitate the
use of these guidelines (Fig 1).
Patients who are candidates for exercise testing may have
stable symptoms of chest pain, may be stabilized by medical
therapy following symptoms of unstable chest pain, or may be
post–myocardial infarction or postrevascularization patients.
The clinician should first address whether the diagnosis of
CAD is certain, based on the patient’s history, electrocardio-
gram, and symptoms of chest pain. The important factors
involved in addressing this question are covered in section II of
this document, which focuses on the use of treadmill exercise
testing for diagnosis.
Even in patients for whom the diagnosis of CAD is certain,
based on age, gender, description of chest pain, and history of
prior myocardial infarction, there usually is a clinical need for
risk or prognostic assessment to determine the need for
possible coronary angiography or revascularization. The po-
tential role of treadmill exercise testing in such patients is
detailed in section III.
Post–myocardial infarction patients represent a common
first presentation of ischemic heart disease. They are a subset
of patients who may need risk or prognostic assessment. This
subgroup is considered in detail in section IV, which includes
a discussion of the implications of acute reperfusion therapy
for interpretation of exercise testing in this population.
II. Exercise Testing in Diagnosis of
Obstructive Coronary Artery Disease
Class I
1. Adult patients (including those with complete right bundle
branch block or less than 1 mm of resting ST depression)
with an intermediate pretest probability of CAD (Table 4),
based on gender, age, and symptoms (specific exceptions
are noted under Classes II and III below).
Class IIa
1. Patients with vasospastic angina.
Class IIb
1. Patients with a high pretest probability of CAD by age,
symptoms, and gender.
2. Patients with a low pretest probability of CAD by age,
symptoms, and gender.
3. Patients with less than 1 mm of baseline ST depression and
taking digoxin.
4. Patients with electrocardiographic criteria for left ventricu-
lar hypertrophy (LVH) and less than 1 mm of baseline ST
depression.
Table 3. Medicare Fees and Volumes of Commonly Used Diagnostic Procedures
Procedure 1996 CPT Code(s)
1996 Total
(Professional and Technical)
Medicare RVUs
1994 Medicare Data
Number
Performed
Percent Charged
by Cardiologists
Percent
Office-Based
Treadmill exercise test 93015 or 93016–93018 3.30 875,780* 67* 66*
Stress echocardiography 93350, 93015 7.95
(plus any Doppler charge)
213,404 78 67
Stress SPECT myocardial perfusion imaging 78465, 93015 17.45
(plus isotope charge)
889,319 † 34
Left heart catheterization with left
ventriculogram and coronary angiography
93510, 93543, 93545,
93555, 93556
66.83 728,763 88 ,1
*These numbers are estimates, after excluding treadmill exercise tests performed with perfusion imaging. †There are no reliable data regarding this percentage.
CPT indicates current procedural terminology; RVUs, relative value units; and SPECT, single-photon emission computed tomography.
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Figure 1. Clinical context for
exercise testing for patients
with suspected ischemic heart
disease. *Electrocardiogram
interpretable unless preexci-
tation, electronically paced
rhythm, left bundle branch
block, or resting ST-segment
depression .1 mm. See text for
discussion of digoxin use, left
ventricular hypertrophy, and
ST depression ,1 mm. **For
example, high-risk if Duke
treadmill score predicts aver-
age annual cardiovascular mor-
tality .3% (see Fig 2 for no-
mogram). CAD indicates
coronary artery disease, ECG,
electrocardiogram; MI, myo-
cardial infarction; and rx, treat-
ment.
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Class III
1. Patients with the following baseline ECG abnormalities:
● Preexcitation (Wolff-Parkinson-White) syndrome
● Electronically paced ventricular rhythm
● Greater than 1 mm of resting ST depression
● Complete left bundle branch block
2. Patients with a documented myocardial infarction or prior
coronary angiography demonstrating significant disease
have an established diagnosis of CAD; however, ischemia
and risk can be determined by testing (see sections III and
IV).
Rationale
The exercise test may be used if the diagnosis of CAD is
uncertain. Although other clinical findings, such as dyspnea on
exertion, resting ECG abnormalities, or multiple risk factors
for atherosclerosis may suggest the possibility of CAD, the
most predictive clinical finding is a history of chest pain or
discomfort. Myocardial ischemia is the most important cause
of chest pain and is most commonly a consequence of under-
lying coronary disease. CAD that has not resulted in sufficient
luminal occlusion to cause ischemia during stress15 can still
lead to ischemic events through spasm, plaque rupture, and
thrombosis, but most catastrophic events are associated with
extensive atherosclerosis. These nonobstructive lesions explain
some of the events that occur after a normal exercise test (see
section III). Although the coronary angiogram has obvious
limitations,16 angiographic lesions remain the clinical gold
standard. Results of correlative studies have been divided over
the use of 50% or 70% luminal occlusion. Meta-analysis of the
studies has not demonstrated that the criteria affect the test
characteristics.
Pretest Probability
The clinician’s estimation of pretest probability of obstruc-
tive CAD is based on the patient’s history (including age,
gender, chest pain characteristics), physical examination and
initial testing, and the clinician’s experience with this type of
problem. Table 4 is a modification of the literature review of
Diamond and Forrester.17 Typical or definite angina makes the
pretest probability of disease so high that the test result does
not dramatically change probability. However, the test can be
performed in these patients for other reasons. Atypical or
probable angina in a 50-year-old man or a 60-year-old woman
is associated with about a 50% probability for CAD. Diagnos-
tic testing is most valuable in this intermediate pretest proba-
bility category, because the test result has the largest potential
effect on diagnostic outcome. Typical or definite angina can be
defined as (1) substernal chest pain or discomfort that is (2)
provoked by exertion or emotional stress and (3) relieved by
rest and nitroglycerin. Atypical or probable angina can be
defined as chest pain or discomfort that lacks one of the three
characteristics of definite or typical angina.18
Detailed nomograms are available incorporating the effects
of a history of prior infarction, electrocardiographic Q waves,
electrocardiographic ST and T-wave changes, diabetes, smok-
ing, and hypercholesterolemia.19 History and electrocardio-
graphic evidence of prior infarction dramatically affects pretest
probability. Diabetes has only a modest impact. Smoking and
hypercholesterolemia have a minimal impact.
Diagnostic Characteristics and Test Performance
Sensitivity and Specificity Sensitivity is the percentage of
patients with a disease who will have an abnormal test.
Specificity is the percentage of patients free of disease who will
have a normal test. The method of calculating these terms is
shown in Table 5.
Cut Point or Discriminant Value. A basic step in applying
any testing procedure for the separation of normal subjects
from patients with disease is to determine a value measured by
the test that best separates the two groups. The problem with
any diagnostic test is that there is a large overlap of measure-
ment values of a test in the groups with and without disease.
All tests used for diagnosis of CAD have considerable overlap
in the range of measurements for the normal population and
for those with heart disease. A certain value (discriminant
value) is used to separate these two groups (ie, 1 mm of
Table 4. Pretest Probability of Coronary Artery Disease by Age, Gender, and Symptoms*
Age
(y) Gender
Typical/Definite
Angina Pectoris
Atypical/Probable
Angina Pectoris
Nonanginal
Chest Pain Asymptomatic
30–39 Men Intermediate Intermediate Low Very low
Women Intermediate Very low Very low Very low
40–49 Men High Intermediate Intermediate Low
Women Intermediate Low Very low Very low
50–59 Men High Intermediate Intermediate Low
Women Intermediate Intermediate Low Very low
60–69 Men High Intermediate Intermediate Low
Women High Intermediate Intermediate Low
*No data exist for patients ,30 or .69 years, but it can be assumed that prevalence of CAD increases with age. In
a few cases, patients with ages at the extremes of the decades listed may have probabilities slightly outside the high or
low range. High indicates .90%; intermediate, 10%–90%; low, ,10%; and very low, ,5%.
268 GIBBONS ET AL. JACC Vol. 30, No. 1
EXERCISE TESTING GUIDELINES July 1997:260–315
ST-segment depression). If the value is set high (ie, 2 mm of
ST-segment depression) to ensure that nearly all normal
subjects have a normal test, giving the test a high specificity,
then a substantial number of those with the disease appear to
be normal, reducing the test sensitivity. There may be reasons
for wanting to adjust a test to have a relatively higher sensitiv-
ity, but sensitivity and specificity are inversely related.
Population Effect. Sensitivity and specificity are inversely
related, affected by the population tested, and determined by
the choice of a cut point or discriminant value. Once a
discriminant value that determines the specificity and sensitiv-
ity of a test is chosen, then the population tested must be
considered. If the population is skewed toward persons with a
greater severity of disease, then the test will have a higher
sensitivity for any cut point chosen. For instance, the exercise
test has a higher sensitivity in the elderly and persons with
three-vessel disease than in younger persons and those with
one-vessel disease. A test can have a lower specificity if it is
used in persons in whom false-positive results are more likely,
such as those with valvular heart disease, LVH, resting ST
depression, and patients taking digoxin.
Predictive Value. The predictive value of a positive test is
another term that defines the diagnostic performance of a test
and is determined by sensitivity and specificity. Table 5 shows
how predictive value is calculated. Note that it is dependent on
the prevalence of disease in the population tested. Table 6
demonstrates how disease prevalence affects the calculation.
The positive predictive value of an abnormal test result is
the percentage of persons with an abnormal test result who
have a disease. Predictive value cannot be estimated directly
from the demonstrated specificity or sensitivity of a test, but it
is dependent on disease prevalence (pretest probability of
disease).
Probability Analysis The information most important to a
clinician attempting to make a diagnosis is the probability of
the patient having or not having the disease once the test result
is known. Such a probability cannot be accurately estimated
from the test result and the diagnostic characteristics of the
test alone. Knowledge of the probability of the patient having
the disease before the test is administered (ie, pretest proba-
bility) is also required. Bayes’ theorem states that the proba-
bility of a patient having the disease after a test is performed
will be the product of the disease probability before the test
and the probability that the test provided a true result. The
clinician often makes this calculation intuitively when he or she
suspects a false result when a 30-year-old woman with atypical
angina has an abnormal exercise test result(low pretest prob-
ability). The same abnormal response would be intuitively
considered a true-positive result in a 60-year-old man with
typical angina pectoris (high pretest probability).
Table 6. Effect of Disease Prevalence on Predictive Value of a Positive Test
Prevalence of
CAD (%) Subjects
Test
Characteristics
Number With
Abnormal
Test Result
Number With
Normal Test
Result
Predictive Value of
a Positive Result
5 500 with CAD 50% sensitive 250 (TP) 250 (FN) 250/(250 1 950)
9500 without CAD 90% specific 950 (FP) 8550 (TN) 5 21%
50 5000 with CAD 50% sensitive 2500 (TP) 2500 (FN) 2500/(2500 1 500)
5000 without CAD 90% specific 500 (FP) 4500 (TN) 5 83%
Calculation of the predictive value of an abnormal test (positive predictive value) using a test with a sensitivity of 50% and a specificity of 90% in two populations
of 10,000 patients, one with a CAD prevalence of 5% and the other with a prevalence of 50%. In a test with characteristics like the exercise ECG, the predictive value
of 1 mm of ST depression increases from 21% when there is a 5% prevalence of disease to 83% when there is a 50% prevalence of disease. Thus, four times as many
of those with an abnormal test result will be found to have coronary disease when the patient population increases from a 5% prevalence of CAD to a 50% prevalence.
These calculations demonstrate the important influence that prevalence has on the positive predictive value. PV1 is the test performance characteristic most apparent
to the clinician using the test. This explains the greater percentage of false-positive results found when the test is used as a screening procedure in an asymptomatic
group (with a low prevalence of CAD) as opposed to when it is used as a diagnostic procedure in patients with symptoms most likely due to CAD (higher prevalence
of CAD). For 5% prevalence: PV1 5 250/(250 1 950) 5 21%. For 50% prevalence: PV1 5 2500/(2500 1 500) 5 83%. CAD indicates coronary artery disease; TP,
true-positive; FN, false-negative; FP, false-positive; and TN, true-negative.
Table 5. Definitions and Calculation of the Terms Used to Quantify the Diagnostic Accuracy of a Test
Sensitivity 5 [TP/(TP 1 FN)] 3 100 Specificity 5 [TN/(FP 1 TN)] 3 100
Predictive value of an abnormal test (PV1) 5
Sensitivity 3 P(CAD)
[Sensitivity 3 P(CAD)] 1 [(1 2 Specificity)[12P(CAD)]]
Predictive accuracy 5 [Sensitivity 3 P(CAD)] 1 [Specificity 3 [1 2 P(CAD)]]
TP indicates those with an abnormal test result and disease (true-positives); TN, those with a normal test result and
no disease (true-negatives); FP, those with an abnormal test result but no disease (false-positives); FN, those with a
normal test result but disease (false-negatives); PV1, the percentage of those with an abnormal (1) test result who have
disease; predictive accuracy, the percentage of correct classifications, both 1 and 2; and P(CAD), pretest probability.
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Scores developed from multivariable analysis of clinical and
exercise test variables provide superior discrimination com-
pared with using only the ST-segment response to diagnose
CAD. Such scores can provide probabilities of CAD that are
more accurate than ST measurements alone.20,21 However,
diagnostic interpretation of the exercise test still centers
around the ST response, because the clinician remains uncer-
tain about which other variables to apply and how to include
them in prediction. Although the statistical models proposed
have proved to be superior, the available equations have
differed as to variables and coefficients chosen. In addition, the
equations were usually derived in study populations with a
higher prevalence of disease than seen in clinical settings
because of work-up bias, ie, the results of the exercise test were
used to decide who would undergo cardiac catheterization. For
these reasons, use of these equations remains controversial
and limited. Several such equations are shown in Appendix 2.
However, when these computational techniques have been
compared with the judgment of experienced clinical cardiolo-
gists, the predictions have been comparable.22,23 Physicians are
often urged to “use” more than just the ST segment in
interpreting the exercise test; these equations provide the only
scientific means to do so.
Believability Criteria for Diagnostic Tests
Studies should include consecutive or randomly selected
patients for whom the diagnosis is in doubt.24 Any diagnostic
test appears to function well if obviously normal subjects are
compared with those who obviously have the disease in ques-
tion (a “limited challenge”). The more relevant issue is to
evaluate patients who are suspected but not known to have the
disease of interest and to differentiate those who do from those
who do not. If the patients enrolled in the study do not
represent this diagnostic dilemma group, the test may perform
well in the study but not in clinical practice. Problems arise
when patients who most certainly have the disease (ie, post–
myocardial infarction patients) are included in this diagnostic
sample. Post–myocardial infarction patients may be included
in studies to predict disease severity but should not be included
in studies attempting to distinguish those with disease from
those without disease.
Diagnostic Accuracy of the Standard Exercise Test
The variability of the reported diagnostic accuracy of the
exercise electrocardiogram (ECG) has been studied by meta-
analysis.25,26 The criteria to judge the credibility and applica-
bility of the results of studies evaluating diagnostic tests27 were
applied. Most of the studies failed to fulfill these criteria,
particularly removal of work-up bias. However, this analysis
provides the best description of the diagnostic accuracy of the
Table 7. Meta-Analyses of Exercise Testing25,26
Grouping
Number of
Studies
Total Number
of Patients
Sens
(%)
Spec
(%)
Predictive
Accuracy (%)
Meta-analysis of standard exercise test 147 24,047 68 77 73
Meta-analysis without MI 58 11,691 67 72 69
Meta-analysis without workup bias 3 . 1000 50 90 69
Meta-analysis with ST depression 22 9153 69 70 69
Meta-analysis without ST depression 3 840 67 84 75
Meta-analysis with digoxin 15 6338 68 74 71
Meta-analysis without digoxin 9 3548 72 69 70
Meta-analysis with LVH 15 8016 68 69 68
Meta-analysis without LVH 10 1977 72 77 74
Sens indicates sensitivity; Spec, specificity; MI, myocardial infarction; and LVH, left ventricular hypertrophy.
Table 8. Studies Including Resting ST Depression
Author Year Total Patients Sensitivity Specificity
Roitman46 1970 100 0.73 0.82
Erikssen74 1977 113 0.84 0.17
Silber75 1979 108 0.71 0.70
Dunn76 1979 125 0.70 0.65
Weiner77 1979 2045 0.79 0.69
Marcomichelakis78 1980 100 0.92 0.62
Morales-Ballejo79 1981 100 0.62 0.74
Machecourt80 1981 112 0.48 0.82
Guiteras81 1982 112 0.79 0.61
Santinga82 1982 113 0.56 0.86
Currie83 1983 105 0.77 0.82
Hlatky84 1984 3094 0.69 0.79
O’Hara85 1985 103 0.69 0.65
Machecourt86 1985 105 0.45 0.80
Huerta87 1985 114 0.90 0.60
Melin88 1985 135 0.61 0.79
Hung89 1985 171 0.85 0.63
Detry90 1985 284 0.64 0.72
Weiner91 1985 617 0.61 0.76
Ananich92 1986 111 0.55 0.92
Vincent93 1986 122 0.68 0.48
Detrano94 1986 303 0.69 0.73
Others (11)* 1974–1986 861 0.71 0.73
Averages with ST
depression
9153 0.69 0.70
*Eleven other studies, each with ,100 subjects, combined.
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exercise test. Meta-analysis of 147 consecutively published
reports (Tables 7 through 13) involving 24 074 patients who
underwent both coronary angiography and exercise testing
revealed a wide variability in sensitivity and specificity (mean
sensitivity was 68%, with a range of 23% to 100% and a
standard deviation of 16%; mean specificity was 77%, with a
range of 17% to 100% and a standard deviation of 17%).
However, only the results in the 58 studies (which included
11 691 patients from this meta-analysis) that removed patients
with a prior myocardial infarction, fulfilling one of the criteria
for evaluating a diagnostic test, accurately portray the perfor-
mance of the test. These studies demonstrated a mean sensi-
tivity of 67% and a mean specificity of 72%. In the few studies
where work-up bias was avoided by having patients agree to
undergo both procedures, fulfilling the other major criterion,
the approximate sensitivity and specificity of 1 mm of horizon-
tal or downward ST depression were 50% and 90%, respec-
tively.28,29 These latter studies provide a true estimate of how
standard ECG criteria perform in patients with chest pain
typically seen by the internist or family practitioner. As men-
tioned previously, sensitivity will be higher in patients with
three-vessel disease and lower in patients with one-vessel
disease. It is apparent that the true diagnostic value of the
exercise ECG lies in its relatively high specificity. The modest
sensitivity of the exercise ECG is generally less than the
sensitivity of imaging procedures.5,6
Sensitivity From Meta-Analysis Sensitivity (percentage of
those with coronary disease who had an abnormal ST re-
sponse) was found to be significantly and independently re-
lated to two study characteristics:
● Sensitivity decreased when equivocal tests were consid-
ered normal.
● Comparison with a new, “better” test lowered the sensi-
tivity of the exercise ECG (publication bias).
Specificity From Meta-Analysis Specificity (percentage of
those without coronary disease who had a normal ST response)
was found to be significantly and independently related to two
variables:
● When upsloping ST depression was classified as abnor-
mal, specificity was lowered and sensitivity increased.
● The use of preexercise hyperventilation was associated
with a decreased specificity, although there is no expla-
Table 9. Studies Excluding Resting ST Depression
Author Year Total Patients Sensitivity Specificity
Sketch95 1980 107 0.64 0.81
Nair96 1983 280 0.66 0.93
Furuse97 1987 135 0.77 0.83
Others* 1971–1984 318 0.59 0.78
Averages without
ST depression
840 0.67 0.84
*Four other studies, each with ,100 subjects, combined.
Table 10. Studies Including Digitalis
Author Year Total Patients Sensitivity Specificity
Roitman46 1970 100 0.73 0.82
Silber75 1979 108 0.71 0.70
Dunn76 1979 125 0.63 0.65
Marcomichelakis78 1980 100 0.92 0.62
Machecourt80 1981 112 0.48 0.82
Currie83 1983 105 0.77 0.82
Nair96 1983 280 0.66 0.93
Hlatky84 1984 3094 0.70 0.85
O’Hara85 1985 103 0.69 0.65
Machecourt86 1985 105 0.45 0.80
Huerta87 1985 114 0.90 0.60
Weiner91 1985 617 0.61 0.76
Ananich92 1986 111 0.55 0.92
Vincent93 1986 122 0.68 0.48
Detrano94 1986 303 0.69 0.73
Others* 1971–1986 839 0.64 0.69
Averages with digitalis 6338 0.68 0.74
*Ten other studies, each with ,100 subjects, combined.
Table 11. Studies Excluding Digitalis
Author Year Total Patients Sensitivity Specificity
Erikssen74 1977 113 0.84 0.17
Weiner77 1979 2045 0.79 0.69
Morales-Ballejo79 1981 100 0.62 0.74
Guiteras81 1982 112 0.79 0.66
Santinga82 1982 113 0.56 0.86
Melin88 1985 135 0.61 0.79
Hung89 1985 171 0.85 0.63
Detry90 1985 284 0.64 0.72
Furuse97 1987 135 0.77 0.83
Others* 1978–1986 340 0.71 0.85
Averages without
digitalis
3548 0.72 0.69
*Five other studies, each with ,100 subjects, combined.
Table 12. Studies Including Left Ventricular Hypertrophy
Author Year Total Patients Sensitivity Specificity
Roitman46 1970 100 0.73 0.82
Erikssen74 1977 113 0.84 0.17
Silber75 1979 108 0.71 0.70
Dunn76 1979 125 0.70 0.65
Weiner77 1979 2045 0.79 0.69
Sketch95 1980 107 0.64 0.81
Machecourt80 1981 112 0.48 0.82
Hlatky84 1984 3094 0.69 0.79
O’Hara85 1985 103 0.69 0.65
Machecourt86 1985 105 0.45 0.80
Huerta87 1985 114 0.90 0.60
Weiner91 1985 617 0.61 0.76
Ananich92 1986 111 0.55 0.92
Vincent93 1986 122 0.68 0.48
Detrano94 1986 303 0.69 0.73
Others* 1974–1986 737 0.67 0.68
Averages with LVH 8016 0.68 0.69
*Nine other studies, each with ,100 subjects, combined. LVH indicates left
ventricular hypertrophy.
271JACC Vol. 30, No. 1 GIBBONS ET AL.
July 1997:260–315 EXERCISE TESTING GUIDELINES
nation for this association. Hyperventilation was once
thought to reveal false-positive ST responders by bringing
out ST depression with a stimulus other than ischemia;
however, this has not been validated, and it is no longer
recommended as a routine to be performed before
standard testing.26
The Tables 8 to 13 in the appendix were developed for
resolving the issues of LVH, resting ST depression, and
digoxin. Of the 58 studies, only those that provided sensitivity,
specificity, and total patient numbers were considered, and
only those with more than 100 patients were considered
separately. Regarding the effect of resting ECG abnormalities,
the studies that included patients with LVH had a mean
sensitivity of 68% and a mean specificity of 69%; the studies
that excluded them had a mean sensitivity of 72% and a mean
specificity of 77%. Studies that included patients with resting
ST depression had a mean sensitivity of 69% and a mean
specificity of 70%; studies that excluded them had a mean
sensitivity of 67% and a mean specificity of 84%. Studies that
included patients receiving digoxin had a mean sensitivity of
68% and a mean specificity of 74%; studies that excluded
patients on digoxin had a mean sensitivity of 72% and a mean
specificity of 69%. Comparing these results with the average
sensitivity of 67% and specificity of 72% as well as to them-
selves, only LVH and resting ST depression appear to lower
specificity. However, other studies in apparently healthy persons
(see below) have suggested that digoxin also lowers specificity.
These meta-analyses provide only indirect evidence regard-
ing these potentially important factors, because they assume
that the study populations were otherwise equal with respect to
characteristics that might influence test performance. This
critical assumption has not been confirmed and may not be
true.
The wide variability in test performance apparent from this
meta-analysis makes it important that clinicians use proper
methods for testing and analysis. Upsloping ST depression
should be considered borderline or negative. Hyperventilation
is no longer routinely recommended before testing.
Influence of Other Factors on Test Performance
Drugs Digoxin. Digoxin produces abnormal exercise-
induced ST depression in 25% to 40% of apparently healthy
normal subjects.30,31 The prevalence of abnormal responses is
directly related to age. Although patients must be off the
medication for at least 2 weeks for its effect to be gone, it is not
necessary to do so before diagnostic testing.32
b-Blocker Therapy. Despite the marked effect of b-blockers
on maximal exercise heart rate, with patients subgrouped
according to b-blocker administration initiated by their refer-
ring physician, no differences in test performance were found
in a consecutive group of men being evaluated for possible
CAD.33 For routine exercise testing, it appears unnecessary for
physicians to accept the risk of stopping b-blockers before
testing when a patient exhibits possible symptoms of ischemia.
However, exercise testing in patients on b-blockers may have
reduced diagnostic value due to inadequate heart rate re-
sponse.
Other Drugs. Various medications, including antihyperten-
sive agents and vasodilators, can affect test performance by
altering the hemodynamic response of blood pressure. Acute
administration of nitrates can attenuate the angina and ST
depression associated with myocardial ischemia. Flecainide
has been associated with exercise-induced ventricular tachy-
cardia (VT).34,35
Electrocardiographic Abnormalities
Left Bundle Branch Block Exercise-induced ST depression
usually occurs with left bundle branch block and has no
association with ischemia.36 Even up to 1 cm of ST depression
can occur in healthy normal subjects.
Right Bundle Branch Block Exercise-induced ST depres-
sion usually occurs with right bundle branch block in the
anterior chest leads (V1 through V3) and is not associated with
ischemia.37 However, in the left chest leads (V5 and V6) or
inferior leads (II and aVF), its test characteristics are similar to
those of a normal resting ECG.
Left Ventricular Hypertrophy With Repolarization Abnor-
malities As discussed previously, this ECG abnormality is
associated with a decreased specificity of exercise testing, but
sensitivity is unaffected. Therefore, a standard exercise test
may still be the first test, with referrals for further tests only
indicated in patients with an abnormal test result.
Resting ST Depression Resting ST-segment depression
has been identified as a marker for adverse cardiac events in
patients with and without known CAD.38–42 Miranda et al43
performed a retrospective study of 223 patients without clinical
or electrocardiographic evidence of prior myocardial infarc-
tion. Women, patients with resting ECGs showing left bundle
branch block or LVH, and those on digoxin or with valvular or
congenital heart disease were excluded. Ten percent had
persistent resting ST-segment depression and nearly twice the
prevalence of severe coronary disease (30%) than those with-
out resting ST-segment depression (16%). Two millimeters
of additional exercise-induced ST-segment depression or
Table 13. Studies Excluding Left Ventricular Hypertrophy
Author Year Total Patients Sensitivity Specificity
Marcomichelakis78 1980 100 0.92 0.62
Morales-Ballejo79 1981 100 0.62 0.74
Guiteras81 1982 112 0.79 0.66
Santinga82 1982 113 0.56 0.86
Currie83 1983 105 0.77 0.82
Nair96 1983 280 0.66 0.93
Melin88 1985 135 0.61 0.79
Hung89 1985 171 0.85 0.63
Detry90 1985 284 0.64 0.72
Furuse97 1987 135 0.77 0.83
Others* 1971–1983 442 0.69 0.84
Averages without LVH 1977 0.72 0.77
*Six other studies, each with ,100 subjects, combined. LVH indicates left
ventricular hypertrophy.
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downsloping depression of 1 mm or more in recovery were
particularly useful markers in these patients for diagnosis of
any coronary disease (likelihood ratio 3.4, sensitivity 67%,
specificity 80%). Smaller studies by Kansal et al44 and Harris et
al45 had similar results.
Other studies have found decreased specificity in patients
with resting ST-segment depression.46,47 However, these stud-
ies included bundle branch blocks, previous infarction, “non-
specific” ST-T changes such as T-wave inversions and/or
flattening; additionally, those with LVH and resting ST-
segment depression were not considered separately. The three
studies that considered isolated resting ST depression and the
meta-analysis support the conclusion that additional exercise-
induced ST-segment depression in patients with resting ST-
segment depression represents a reasonably sensitive indicator
of CAD.
Overview of Confounders: Digoxin, Resting ST
Depression, and Left Ventricular Hypertrophy
The meta-analysis was reprocessed, considering the status
of digoxin, resting ST depression, and LVH as exclusion
criteria in the 58 studies that excluded patients with a myocar-
dial infarction. Only those that included at least 100 patients
and provided patient numbers as well as both sensitivity and
specificity were considered in the average. Those studies with
less than 100 patients were averaged together as “other”
studies. The results are summarized in Tables 7 to 13. Al-
though specificity is lowered in the presence of resting ST
depression of less than 1 mm, the standard exercise test is still
the first test option. There is a divergence of opinion regarding
patients taking digoxin with less than 1 mm of ST depression
and those with LVH with less than 1 mm of resting ST
depression, but the standard exercise test is still a reasonable
first test opinion in such patients. If the test result is negative,
the likelihood of CAD is substantially reduced, but if an
abnormal response is obtained, further testing is indicated.
Resting ST-segment depression is a marker for a higher
prevalence of severe CAD and is associated with a poor
prognosis; standard exercise testing continues to be diagnosti-
cally useful in these patients. In the published data there are
few patients with resting ST depression greater than 1 mm. It
was the consensus of the committee that exercise testing is
unlikely to provide important diagnostic information in such
patients and that exercise imaging modalities are preferred in
this subset of patients.
ST-Segment Interpretation Issues
Lead Selection Lead V5 alone consistently outperforms
the inferior leads and the combination of lead V5 with II,
because lead II has a high false-positive rate. In patients
without prior myocardial infarction and normal resting ECGs,
the precordial leads alone are a reliable marker for CAD, and
monitoring of inferior limb leads adds little additional diag-
nostic information. In patients with a normal resting ECG,
exercise-induced ST-segment depression confined to the infe-
rior leads is of little value for identification of coronary
disease.48
Upsloping ST Depression Downsloping ST-segment de-
pression is a stronger predictor of CAD than horizontal
depression, and both are more predictive than upsloping
depression. However, patients with slowly upsloping ST-
segment depression, for example, when the slope is less than
1 mV/s, probably have an increased probability of coronary
disease.49,50 If a slowly ascending slope is used as a criterion for
abnormal, the specificity of exercise testing will be decreased
(more false-positive results), although the test becomes more
sensitive. The committee favored the use of the more com-
monly used definition for a positive test: 1 mm of horizontal or
downsloping ST depression (zero or negative slope visually).
ST Elevation Early repolarization is a common resting
pattern of ST elevation in normal persons. Exercise-induced
ST-segment elevation is always considered from the baseline
ST level. ST elevation is relatively common after a Q-wave
infarction, but ST elevation in leads without Q waves occurs in
only 1 of 1000 patients seen in a typical exercise laboratory.51–57
ST elevation on a normal ECG (other than in aVR or V1)
represents transmural ischemia (caused by spasm or a critical
lesion), is very rare (0.1% in a clinical lab), and in contrast to
ST depression is very arrhythmogenic and localizes the isch-
emia. When it occurs in leads V2 through V4, the left anterior
descending artery is involved, in the lateral leads the left
circumflex and diagonals are involved; and in leads II, III, and
aVF the right coronary artery is involved. When the resting
ECG shows Q waves of an old myocardial infarction, the
significance of ST elevation is controversial. Some studies have
suggested that ST elevation is due to wall motion abnormali-
ties58,59; other studies have found it to be a marker of residual
viability in the infarcted area.60–62 Accompanying ST depres-
sion in such patients can be due to a second area of ischemia
or reciprocal changes.
R-Wave Changes Many factors affect the R-wave ampli-
tude response to exercise,63 and the response does not have
diagnostic significance.64,65 R-wave amplitude typically in-
creases from rest to submaximal exercise, perhaps to a heart
rate of 130 beats per minute (bpm), then decreases to a
minimum at maximal exercise.66 If a patient were limited by
objective signs or subjective symptoms, R-wave amplitude
would increase from rest to such an end point. Such patients
may be demonstrating a normal R-wave response but are
classified as abnormal because of a submaximal effort.
Exercise-induced changes in R-wave amplitude have no inde-
pendent predictive power but are associated with CAD be-
cause such patients are often submaximally tested, and an
R-wave decrease normally occurs at maximal exercise. Adjust-
ing the amount of ST-segment depression by the R-wave
height has not been shown to consistently improve the diag-
nostic value of exercise-induced ST depression.
Heart Rate Adjustment Several methods of heart rate
adjustment have been proposed to increase the diagnostic
accuracy of the exercise ECG. The maximal slope is computed
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either manually 67 or by computer.68 A second technique
divides the difference between ST depression at peak exercise
by the exercise-induced increase in heart rate.69,70 Although
the initial reports were promising, neither meta-analysis25 nor
a subsequent study71 found convincing evidence of benefit. The
potential explanations for these discordant findings are de-
tailed elsewhere.71,72 As described in sections III and IV, it is
more important to consider exercise capacity rather than
exercise heart rate in interpretation of exercise tests.
Computer Processing Although computer processing of
the exercise ECG can be helpful, it can result in a false-positive
indication of ST depression.73 To avoid this problem, the
physician should always be provided with ECG recordings of
the raw unprocessed ECG data for comparison with any
averages the exercise test monitor generates. It is preferable
that averages always be contiguously preceded by the raw ECG
data. The degree of filtering and preprocessing should always
be presented along with the ECG recordings and should be
compared with the AHA recommendations (0 to 100 Hz using
notched power line frequency filters). It is preferable that the
AHA standards be the default setting. All averages should be
carefully labeled and explained, particularly those that simu-
late raw data. Simulation of raw data with averaged data
should be avoided. Obvious breaks should be inserted between
averaged ECG complexes. Averages should be check marked
to indicate the PR isoelectric line as well as the ST measure-
ment points. None of the computerized scores or measure-
ments have been sufficiently validated to recommend their
widespread use.
III. Risk Assessment and Prognosis in
Patients With Symptoms or a Prior History
of Coronary Artery Disease
Class I
1. Patients undergoing initial evaluation with suspected or
known CAD. Specific exceptions are noted below in Class
IIb.
2. Patients with suspected or known CAD previously evalu-
ated with significant change in clinical status.
Class IIb
1. Patients with the following ECG abnormalities:
● Preexcitation (Wolff-Parkinson-White) syndrome
● Electronically paced ventricular rhythm
● Greater than 1 mm of resting ST depression
● Complete left bundle branch block
2. Patients with a stable clinical course who undergo periodic
monitoring to guide treatment.
Class III
1. Patients with severe comorbidity likely to limit life expect-
ancy and/or candidacy for revascularization.
Risk Stratification: General Considerations
Risk or prognostic stratification is one of the pivotal
activities in medical practice. Virtually all patient management
decisions are driven by the clinician’s assessment of the
patient’s prognosis. During the initial encounter, the physician
collects a standard data set of history, physical exam, and
laboratory test data items. Using these data, the physician
formulates a working diagnosis and risk assessment and selects
an initial management strategy.98 This strategy may consist of
additional noninvasive testing, referral for prompt cardiac
catheterization, or performance of a therapeutic trial. The
additional data resulting from these management steps may
affirm the initial risk assessment, cause it to be modified, or
result in a completely revised risk assessment. The updated risk
assessment in turn may indicate the need for further testing
and/or therapy. Each additional patient-physician encounter
provides an opportunity to update the risk assessment and
modify the therapeutic plan appropriately.
The most important implication of the foregoing for these
guidelines is that risk stratification with the exercise test does
not take place in isolation but as part of a process that includes
more readily accessible (and sometimes less expensive) data
from the clinical exam and other laboratory tests. Thus, the
value of exercise testing for risk stratification must be consid-
ered in light of what is added to that which is already known
about the patient’s risk status.
Whereas prognosis typically refers to probability of survival,
other outcomes such as freedom from myocardial infarction,
symptom status, functional capacity, and other aspects of
quality of life are equally important to many patients. Most
research on exercise testing, however, has concentrated on the
relation between test parameters and future survival (and, to a
lesser extent, freedom from myocardial infarction). These
outcomes will be primarily considered in this section of the
guidelines.
Prognosis of Coronary Artery Disease:
General Considerations
CAD is a chronic disorder with a natural history that spans
multiple decades. In each affected individual the disease
typically cycles in and out of a number of clinically defined
phases: asymptomatic or presymptomatic, stable angina, pro-
gressive angina, unstable angina, or acute myocardial infarc-
tion. Although the specific approach to risk stratification of the
coronary disease patient can vary according to the phase of the
disease in which the patient presents, some general concepts
apply across the coronary disease spectrum.
Conceptually the probability of cardiac death in a patient
with CAD can be viewed as the sum of the risks at the time of
evaluation (the current risk state) and the risk that the disease
will progress over time to a higher or lower risk state. The
patient’s current risk state is a function of five major types of
prognostic measures (Table 14). The strongest predictor of
long-term survival with CAD is function of the left ventricle. In
particular, the extent of damage or dysfunction and the success
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of mechanisms used by the cardiovascular system to compen-
sate for that damage are of paramount importance. Many
different clinical and laboratory parameters provide informa-
tion about the extent of left ventricular dysfunction (Table 14).
Ejection fraction is the most commonly used measure, but it
alone does not completely describe the prognostic information
in left ventricular function. Another group of prognostic
factors describes the anatomic extent and severity of athero-
sclerotic involvement of the coronary tree. The number of
diseased vessels is the most common measure of this domain.
More details about the coronary anatomy add important
prognostic information to this simple measure. A third group
of prognostic factors provides evidence of a recent coronary
plaque rupture, indicating a substantially increased short-term
risk for cardiac death or nonfatal myocardial infarction. Wors-
ening clinical symptoms with unstable features is the major
clinical marker of a plaque event. The fourth group of prog-
nostic factors is related to the presence of electrical instability
of the myocardium and the propensity for malignant ventric-
ular arrhythmia. The final group of prognostic factors de-
scribes general health and noncoronary comorbidity.
The probability that a given patient will progress to a
higher- or lower-risk disease state depends primarily on factors
related to the aggressiveness of the underlying atherosclerotic
process (Table 14). Patients with the major cardiac risk factors,
including smoking, hypercholesterolemia, diabetes mellitus,
and hypertension, are most likely to evidence progressive
atherosclerosis with repeated coronary plaque events. Patients
with symptomatic coronary disease at a younger age also may
have a more aggressive disease process.
A growing body of pathological, angiographic, angioscopic,
and intravascular ultrasonographic data support a pathophys-
iological model in which most major cardiac events (sudden
death, acute myocardial infarction, unstable angina) are initi-
ated by microscopic ruptures of high-risk or vulnerable athero-
sclerotic plaques. Characteristically, vulnerable plaques have a
cholesterol gruel core and a thin fibrous cap. Various nonspe-
cific factors may act as triggers and cause a vulnerable plaque
to rupture at thinned sites around the shoulders of the cap.
This exposes inner plaque material to the flowing intra-arterial
blood and initiates formation of a platelet-fibrin thrombus over
the area of rupture. Clinically the rupture may seal without
detectable sequelae, or the patient may experience worsening
angina, acute myocardial infarction, or sudden cardiac death.
Several lines of evidence have shown that the majority of
vulnerable plaques appear “angiographically insignificant” be-
fore rupture (ie, less than 75% diameter stenosis). In contrast,
most “significant” plaques (greater than or equal to 75%
stenosis) visualized at angiography are at low risk for plaque
rupture. Thus, the ability of stress testing of any type to detect
vulnerable atherosclerotic lesions may be limited by the
smaller size and lesser effect on coronary blood flow of these
plaques and may explain the occasional acute coronary event
that may occur not long after a negative treadmill test.
Risk Stratification With the Exercise Test
The major exercise ECG testing measures that have been
proposed as prognostic markers are listed in Table 15. Because
the exercise test is a diagnostic tool rather than a therapy, its
effect on patient outcomes is necessarily indirect. To the extent
that the test guides clinicians to select more appropriate or
effective therapies, the exercise test will improve outcomes.
However, no randomized trials of exercise testing versus no
exercise testing have been performed. The entire evidence
base for exercise testing therefore consists of observational
studies. No direct evidence links different exercise testing
strategies with differing outcomes.
As described previously, the risks of exercise testing in
appropriately selected candidates are extremely low. Thus, the
main arguments for not performing an exercise test in many
clinical situations are that the information provided would not
justify the extra costs of obtaining that information (ie, the test
would not be cost-effective in that given situation) and/or the
test might provide misleading information that could lead to
inappropriate or unnecessary additional testing or therapy
(both of which may have higher risks than exercise testing).
In reviewing the published evidence in this area, the
Table 14. Prognostic Factors for Patients With Coronary Disease
Prognostic factors for current risk state
Left ventricular function/damage
History of prior MI
Pathologic Q waves on the resting ECG
Congestive heart failure symptoms
Cardiomegaly on the chest x-ray
Ejection fraction
End-systolic volume
Regional LV wall motion abnormalities
Conduction disturbances on the ECG
Mitral regurgitation
Exercise duration/tolerance
Severity of CAD
Anatomic extent and severity of CAD
Collateral vessels present
Transient ischemia on ambulatory monitor
Exercise- or stress-induced ST deviation
Coronary plaque event
Progressive or unstable ischemic symptoms
Transient ischemia on resting ECG
Electrical stability
Ventricular arrhythmias
General health
Age
Noncoronary comorbidity
Prognostic factors for change in risk state
Factors predisposing to disease progression
Smoking
Hyperlipidemia
Diabetes mellitus
Hypertension
Other genetic/metabolic factors
MI indicates myocardial infarction; ECG, electrocardiogram; LV, left ven-
tricular; and CAD, coronary artery disease.
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subcommittee focused on studies that examined hard cardiac
outcome events (death alone or death plus myocardial infarc-
tion) and had at least five (and preferably 10) outcome events
for every candidate variable evaluated. Use of appropriate
multivariable statistical techniques was also a requirement for
selection. Special emphasis was given to studies that evaluated
the incremental effects of the exercise test beyond the prog-
nostic information available from the clinical evaluation (his-
tory, physical examination, and resting 12-lead ECG).
Symptomatic Patients With Nonacute Coronary Artery
Disease Unless cardiac catheterization is indicated, patients
with suspected or known CAD and new or changing symptoms
suggesting ischemia should generally undergo exercise testing
to assess the risk of future cardiac events. As described in the
ACC/AHA guidelines for percutaneous transluminal coronary
angioplasty and for coronary artery bypass grafting, documen-
tation of exercise- or stress-induced ischemia is desirable for
most patients who are being evaluated for revascularization.3,4
Choice of initial stress testing modality should be based on
evaluation of the patient’s resting ECG, physical ability to
perform exercise, and local expertise and technology. For risk
assessment, the exercise test should be the standard initial
mode of stress testing used in patients with a normal ECG who
are not taking digoxin.99–101 Patients with widespread resting
ST depression (greater than or equal to 1 mm), complete left
bundle branch block, ventricular paced rhythm, or preexcita-
tion should usually be tested with an imaging modality. Exer-
cise testing may still provide useful prognostic information in
patients with these ECG changes but cannot be used to identify
ischemia. Patients unable to exercise because of physical limita-
tions affecting exercise capacity (eg, arthritis, amputations, severe
peripheral vascular disease, severe chronic obstructive pulmonary
disease, general debility), should undergo pharmacological stress
testing in combination with imaging.
In patients with suspected or known symptomatic coronary
disease, exercise testing can be used to estimate prognosis and
assist in management decisions. The primary evidence in this
area consists of seven observational studies of the prognostic
value of the exercise ECG (Table 16). An overview of the
available literature has shown some inconsistency among stud-
ies in the exercise variables identified as independent prognos-
tic factors. These differences are at least partially attributable
to differences in the spectrum of patients referred for testing,
the amount of crossover to coronary revascularization, and the
sample size/statistical power of the analysis.109
One of the strongest and most consistent prognostic mark-
ers identified in exercise testing is maximum exercise capacity,
which is at least partly influenced by the extent of resting left
ventricular dysfunction and the amount of further LV dysfunc-
tion induced by exercise. However, the relation between
exercise capacity and LV function is complex, because exercise
capacity is also affected by age, general physical conditioning,
comorbidities, and psychological state (especially the presence
of depression).110 Several exercise parameters can be used as
markers of exercise capacity (Table 15), including maximal
exercise duration, maximum MET level achieved, maximum
workload achieved, maximum heart rate, and double product.
When interpreting the exercise test, it is very important to take
exercise capacity into account; the specific variable used to
summarize this aspect of test performance is less important.
The translation of exercise duration or workload into METs
(oxygen uptake expressed in multiples of basal oxygen uptake,
3.5 O2 mL/kg per minute) has the advantage of providing a
common measure of performance regardless of the type of
exercise test or protocol used. Although such translations are
based on approximations and are not as accurate for individual
patients as measured maximal oxygen uptake (VO2max),
VO2max has not been studied for prognostic purposes in large
series of patients with chest pain.
A second group of prognostic exercise testing markers
relates to exercise-induced ischemia. These markers include
exercise-induced ST-segment depression, exercise-induced ST-
segment elevation (in leads without pathological Q waves and
not in aVR), and exercise-induced angina. In a large exercise
testing cohort, exercise ST deviation (elevation or depression)
best summarized the prognostic information from this area.103
Other less powerful prognostic ST variables included the
number of leads showing significant ST-segment depression,
configuration of the exercise-induced ST depression (down-
sloping, horizontal, or upsloping), and duration of ST devia-
tion into the recovery phase of the test.
Two early influential studies of exercise treadmill testing
and prognosis were reported from the Duke Cardiovascular
Disease Databank and the Coronary Artery Surgery Study
Registry. Using the Duke database, McNeer and coworkers111
demonstrated that an “early positive” exercise test result (ST
depression greater than or equal to 1 mm in the first two stages
of the Bruce protocol) identified a high-risk population,
Table 15. Measurements Available From the Exercise
Treadmill Test
Electrocardiographic
Maximum ST depression
Maximum ST elevation
ST-depression slope (downsloping, horizontal, upsloping)
Number of leads showing ST changes
Duration of ST deviation into recovery
ST/HR indexes
Exercise-induced ventricular arrhythmias
Time to onset of ST deviation
Hemodynamic
Maximum exercise heart rate
Maximum exercise systolic blood pressure
Maximum exercise double product (HR 3 BP)
Total exercise duration
Exertional hypotension (drop below preexercise value)
Chronotropic incompetence
Symptomatic
Exercise-induced angina
Exercise-limiting symptoms
Time to onset of angina
HR indicates heart rate; and BP, blood pressure.
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whereas patients who could exercise into stage IV were at low
risk regardless of the ST response. Weiner and colleagues,102
using the Coronary Artery Surgery Study Registry, analyzed
4083 medically treated patients and identified 12% as high risk
on the basis of greater than or equal to 0.1 mV exercise-
induced ST-segment depression and inability to complete stage
I of the Bruce protocol. These patients had an average annual
mortality rate of 5% per year. Patients who could exercise to at
least stage III of the Bruce protocol without ST-segment
changes (34%) constituted the low-risk group (estimated an-
nual mortality, less than 1%).
Several recent studies have attempted to incorporate multiple
exercise variables into a prognostic score. Using Cox regression
analysis, Mark and colleagues103 created the Duke treadmill score
using data from 2842 inpatients with known or suspected CAD
who underwent exercise tests before diagnostic angiography.
None of the patients had prior revascularization or recent myo-
cardial infarction. The resulting treadmill score was calculated:
treadmill score 5 exercise time 2 5 3 (amount of ST-segment
deviation in millimeters) 2 4 3 exercise
angina index (which had a value of 0 if there
was no exercise angina, 1 if exercise angina
occurred, and 2 if angina was the reason the
patient stopped exercising).
The high-risk group defined by this score (score less than or
equal to 211, 13% of patients) had an average annual cardio-
vascular mortality greater than or equal to 5%. Low-risk
patients had a score greater than or equal to 15 (34% of
patients) and an average annual cardiovascular mortality rate
of 0.5%. In multivariable Cox regression analysis, the Duke
treadmill score added significant prognostic information to
the standard clinical data plus the major catheterization
variables (number of diseased vessels, ejection fraction). To
improve ease of use, the Duke treadmill score was converted
into a nomogram (Fig 2). The score has subsequently been
validated in 613 outpatients at Duke who did not all go on
to coronary angiography and in exercise-testing populations
at several other centers.112–114 The treadmill score was even
more useful for outpatients: approximately two thirds had
treadmill scores indicating low risk. Preliminary data sug-
gest that the score works equally well with men and wom-
en.115 A limitation is the small number of elderly patients
represented in studies evaluating this score.
Froelicher and colleagues104 have developed a prognostic
score using 2546 patients from Long Beach Veterans Admin-
istration Hospital. This score includes two variables in com-
mon with the Duke treadmill score (exercise duration or the
MET equivalent and millimeters of ST changes) and two
different variables (drop in exercise systolic blood pressure
Table 16. Prognostic Studies of Exercise Testing
Study
Years of
Enrollment N
Length of
Follow-up (y) Independent Prognostic Factors
CASS102 1974–1979 4083 5 1. CHF
2. TM stage
3. Exercise-induced ST depression
Duke103 1969–1981 2842 5 1. Exercise-induced ST deviation
2. Exercise-induced angina
3. Exercise duration
Long Beach VA104 1984–1990 2546 5 1. CHF/digoxin use
2. METs
3. Max SBP
4. Exercise-induced ST depression
Italian CNR105 1976–1979 1083 5.5 1. Q wave
2. Prior MI
3. Effort ischemia
4. Exercise capacity
Belgian106 1978–1985 470 5 1. Age
2. Score of maximum HR, ST depression,
angina, watts, ST slope
German107 1975–1978 1238 4.5 1. Exercise tolerance (watts)
2. Maximum HR
Seattle Heart Watch108 1971–1974 733 3.3 1. CHF
2. Maximum double product
3. Max SBP
4. Angina
5. Resting ST depression
CASS indicates Coronary Artery Surgery Study; CHF, congestive heart failure; TM, treadmill; VA, Veterans
Administration; METs, metabolic equivalents; Max, maximum; SBP, systolic blood pressure; CNR, Consiglio Nazionale
Ricerche; MI, myocardial infarction; and HR, heart rate.
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below resting value and history of congestive heart failure or
use of digoxin). The score is calculated as:
53 (CHF/Dig [yes51; no50]) 1 exercise-induced ST depres-
sion in millimeters 1 change in systolic blood pressure score 2
METs, where systolic blood pressure 5 0 for increase greater
than 40 mm Hg, 1 for increase of 31 to 40 mm Hg, 2 for
increase of 21 to 30 mm Hg, 4 for increase of 0 to 11 mm Hg,
and 5 for a reduction below standing systolic preexercise blood
pressure.
Using this score, 77% of the Long Beach VA population
were at low risk (with less than 2% average annual mortality),
18% were at moderate risk (average annual mortality, 7%),
and 6% were at high risk (average annual mortality, 15%).
There is no compelling evidence in patients who are
classified as low risk based on clinical and exercise testing
information that an imaging modality adds significant new
prognostic information to a standard exercise test. In this
regard a distinction should be made between studies that show
a statistical advantage of imaging studies over exercise ECG
alone and studies that demonstrate that the imaging data
would change practice (eg, by shifting patients from moderate-
to low- or high-risk categories). Because of its simplicity, lower
cost, and widespread familiarity in its performance and inter-
pretation, the standard treadmill ECG is the most reasonable
exercise test to select in men with a normal resting ECG who
are able to exercise. In patients with an intermediate-risk
treadmill score, myocardial perfusion imaging appears to be of
value for further risk stratification.114
The optimal testing strategy remains less well defined in
women. Until adequate data are available to resolve this issue,
it is reasonable to use exercise testing for risk stratification in
women as readily as in men with proper consideration of the
importance of the pretest risk state.
One important issue that has received inadequate study is
the relative value of exercise testing for predicting future
cardiac deaths versus future myocardial infarctions (fatal or
nonfatal). Pathophysiological considerations based on the cor-
onary plaque event model described earlier suggest that acute
myocardial infarctions caused by rupture of a relatively small
vulnerable plaque would be difficult to predict accurately using
exercise test parameters. For example, in one large cohort the
predictive power of exercise ST depression for cardiovascular
death alone and cardiovascular death plus nonfatal myocardial
infarction were almost identical, despite the fact that adding
Figure 2. Nomogram of the prognostic relations embodied in the
treadmill score. Prognosis is determined in five steps: (1) The observed
amount of exercise-induced ST-segment deviation (the largest eleva-
tion or depression after resting changes have been subtracted) is
marked on the line for ST-segment deviation during exercise. (2) The
observed degree of angina during exercise is marked on the line for
angina. (3) The marks for ST-segment deviation and degree of angina
are connected with a straight edge. The point where this line intersects
the ischemia-reading line is noted. (4) The total number of minutes of
exercise in treadmill testing according to the Bruce protocol (or the
equivalent in multiples of resting oxygen consumption [METs] from an
alternative protocol) is marked on the exercise-duration line. (5) The
mark for ischemia is connected with that for exercise duration. The
point at which this line intersects the line for prognosis indicates
the 5-year cardiovascular survival rate and average annual cardiovas-
cular mortality for patients with these characteristics. Patients with
,1 mm of exercise-induced ST-segment depression should be counted as
having 0 mm. Angina during exercise refers to typical effort angina or
an equivalent exercise-induced symptom that represents the patient’s
presenting complaint. This nomogram applies to patients with known
or suspected coronary artery disease, without prior revascularization or
recent myocardial infarction, who undergo exercise testing before
coronary angiography. Modified from Mark et al.112
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the nonfatal events should have substantially boosted the
predictive power (ie, more outcome events should yield better
power in prognostic models).103 In another exercise cohort
with long-term follow-up, no relation between exercise capac-
ity and the probability of a follow-up nonfatal myocardial
infarction was found.116 Available data suggest that the exer-
cise test results give a better guide to the likelihood that a
patient will die (given that a plaque event occurs) than they do
to the likelihood of a nonfatal myocardial infarction. This
presumably occurs because patients with severe and/or exten-
sive coronary disease are much less likely to withstand the
challenge to their myocardial circulation caused by a major
plaque event. However, it is difficult to relate the pathophysiology
of coronary events directly to the results of observational epide-
miological studies. There may, for example, be a correlation
between the presence and number of nonobstructive vulnerable
or high-risk plaques and the total coronary atherosclerotic burden
(obstructive and nonobstructive). Exercise test results are, in turn,
correlated with the presence and severity of obstructive coronary
disease.
Patients With Unstable Angina Unstable angina repre-
sents an acute phase in the life cycle of the patient with chronic
coronary disease. It may be a presenting feature or may
interrupt a quiescent phase of clinically manifested disease.
The natural history of unstable angina involves progression to
either death or myocardial infarction on the one hand or
return to the chronic stable phase of CAD on the other. These
events typically play out over a period of 4 to 6 weeks. Thus,
the role and timing of exercise testing in unstable angina
relates to this acute and convalescent period.
The Agency for Health Care Policy and Research14 recently
published guidelines for the diagnosis and treatment of unsta-
ble angina, which have been endorsed by the ACC and the
AHA. A clinical risk stratification algorithm useful for select-
ing the initial management strategy is seen in Table 17.
Patients are separated into low-, moderate-, or high-risk
groups based on history, physical examination, and initial
12-lead ECG. Low-risk patients in this scheme can typically
be treated on an outpatient basis. Most moderate-risk
patients can be cared for in a monitored hospital bed, while
high-risk patients are typically admitted to an intensive care
unit.
Exercise or pharmacological stress testing should generally
be an integral part of the evaluation of low-risk patients with
unstable angina who are evaluated on an outpatient basis. In
most cases testing should be performed within 72 hours of
presentation. In low- or moderate-risk patients with unstable
angina who have been hospitalized for evaluation, exercise
or pharmacological stress testing should generally be per-
formed unless cardiac catheterization is indicated. Testing
can be performed when patients have been free of active
ischemic or heart failure symptoms for a minimum of 48
hours.14 In general, as with patients with stable angina, the
exercise treadmill test should be the standard mode of stress
testing in patients with a normal resting ECG who are not
taking digoxin.
A majority of patients with unstable angina have an under-
lying ruptured plaque and significant CAD. Some have a
ruptured plaque without angiographically significant lesions in
any coronary segment. Still others have no evidence of a
ruptured plaque or atherosclerotic coronary lesions. Very little
evidence exists with which to define the safety of early exercise
testing in unstable angina.117 In addition, many available
studies contain both unstable angina and post–myocardial
infarction patients.
The limited evidence available supports the use of exercise
Table 17. Short-Term Risk of Death or Nonfatal Infarction in Patients With Unstable Angina
High Risk Intermediate Risk Low Risk
At least one of the following features must
be present
No high-risk feature but any of the following
features must be present:
No high- or intermediate-risk feature but may have
any of the following features:
Prolonged, ongoing (.20 min) pain at rest Prolonged (.20 min) resting angina, now
resolved, with moderate or high likelihood
of CAD
Increased frequency, severity, or duration of angina
Pulmonary edema, most likely related to
ischemia
Resting angina (.20 min or relieved with
rest or sublingual nitroglycerin)
Angina provoked at a lower threshold
Angina at rest with dynamic ST changes
$1 mm
Nocturnal angina New-onset angina with onset 2 weeks to 2 months
before presentation
Angina with new or worsening MR murmur Angina with dynamic T-wave changes Normal or unchanged ECG
Angina with S3 or new/worsening rales New-onset CCSC III or IV angina in the
past 2 weeks with moderate or high
likelihood of CAD
Angina with hypotension Pathological Q waves or resting ST
depression $1 mm in multiple-lead
groups (anterior, inferior, lateral)
Age .65 y
This table offers general guidance and illustration rather than rigid algorithms. Estimation of the short-term risks of death and nonfatal myocardial infarction in
unstable angina is a complex multivariable problem that cannot be fully specified in a table such as this. From AHCPR Clinical Practice Guideline, Number 10.14 CAD
indicates coronary artery disease; MR, mitral regurgitation; ECG, electrocardiogram; and CCSC, Canadian Cardiovascular Society class.
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testing in patients with appropriate indications as soon as the
patient has stabilized clinically. Larsson and colleagues118
compared a symptom-limited predischarge (3 to 7 days) exer-
cise test with a test performed at 1 month in 189 patients with
unstable angina or non–Q-wave infarction. The prognostic
value of the two tests was similar, but the earlier test identified
additional patients who would experience events during the
period before the 1-month exercise test. In this population
these earlier events represented one half of all events occur-
ring during the first year.
The Research on Instability in Coronary Artery Disease
(RISC) study group119 examined the use of predischarge
symptom-limited bicycle exercise testing in 740 men admitted
with unstable angina (51%) or non–Q-wave myocardial infarc-
tion (49%). The major independent predictors of 1-year
infarction-free survival in multivariable regression analysis
were the number of leads with ischemic ST-segment depres-
sion and peak exercise workload achieved.
Use of Exercise Test Results in Patient Treatment
As a diagnostic technique, exercise testing has no direct
effect on patient outcomes. It is only through judicious use of
the information gained that the test is linked with improved
outcomes. Thus, the post–exercise test prognosis or risk points
to a particular management strategy that is viewed as most
appropriate (based on expected outcomes).
There is little evidence linking different exercise-defined
risk groups with alternative classes of medical therapy. How-
ever, the results of exercise testing may be used to titrate
medical therapy up to a desired level. The other major manage-
ment step addressed by exercise testing is whether to proceed
with additional testing (which might ultimately lead to revascu-
larization). An important caveat is that decisions about additional
testing (especially cardiac catheterization) must take into account
patient preferences and comorbidity. Patients with severe coex-
isting diseases that make them poor candidates for revasculariza-
tion in general should be managed without invasive evaluation,
regardless of the results of stress testing.
Patients with a low-risk exercise test result (eg, those with a
predicted average annual cardiac mortality less than or equal
to 1% per year) can be treated medically without need for referral
to cardiac catheterization. Patients with a high-risk exercise test
result (eg, patients with a strongly positive test result in Fig 2 or
predicted average annual cardiac mortality greater than or equal
to 4% per year) should usually be referred for cardiac cathe-
terization. Patients with an intermediate-risk exercise test
result (eg, predicted average annual cardiac mortality of 2% to
3% per year) should be referred for additional testing, either
cardiac catheterization or an exercise imaging study. An
intermediate-risk stress test result in a patient with evidence of
left ventricular dysfunction should usually prompt referral for
cardiac catheterization.
IV. After Myocardial Infarction
Class I
1. Before discharge for prognostic assessment, activity pre-
scription, evaluation of medical therapy (submaximal at
about 4 to 7 days).*
2. Early after discharge for prognostic assessment, activity
prescription, evaluation of medical therapy, and cardiac
rehabilitation if the predischarge exercise test was not done
(symptom-limited/about 14 to 21 days).*
3. Late after discharge for prognostic assessment, activity
prescription, evaluation of medical therapy, and cardiac
rehabilitation if the early exercise test was submaximal
(symptom-limited/about 3 to 6 weeks).*
Class IIa
1. After discharge for activity counseling and/or exercise train-
ing as part of cardiac rehabilitation in patients who have
undergone coronary revascularization.
Class IIb
1. Before discharge in patients who have undergone cardiac
catheterization to identify ischemia in the distribution of a
coronary lesion of borderline severity.
2. Patients with the following ECG abnormalities:
● Complete left bundle branch block
● Preexcitation syndrome
● Left ventricular hypertrophy
● Digoxin therapy
● Greater than 1 mm of resting ST-segment depression
● Electronically paced ventricular rhythm
3. Periodic monitoring in patients who continue to participate
in exercise training or cardiac rehabilitation.
Class III
1. Severe comorbidity likely to limit life expectancy and/or
candidacy for revascularization.
The above recommendations, the text, and Fig 3 are largely
based on the ACC/AHA guidelines for the management of
patients with acute myocardial infarction.2 Although some of
the evidence is presented in more detail here and a few recent
references are added, the committee did not feel that there was
sufficient new evidence to justify a major revision of the
previously published recommendations.
Exercise testing is useful in evaluation and treatment of
patients after myocardial infarction. As therapies and treat-
ment strategies for myocardial infarction have changed dra-
matically, particularly over the past decade, the current role of
exercise testing must be viewed in the context of the patients
who present for testing. Shorter hospital stays, widespread use
*Exceptions are noted under Classes IIb and III.
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of thrombolytic agents, greater use of revascularization strat-
egies, and increased use of b-adrenergic blocking agents and
angiotensin converting enzyme inhibitors continues to change
the clinical presentation of the postinfarction patient.120–125
Not all patients will have received each of these various
therapies; hence, survivors of myocardial infarction are quite
heterogeneous. The Canadian Assessment of Myocardial In-
farction (CAMI) study121 reported that among 3178 consecu-
tive patients with acute myocardial infarction, 45% received
thrombolytic agents, 20% underwent coronary angioplasty,
and 8% had coronary artery bypass surgery. Medications at the
time of hospital discharge included b-blockers in 61%, angio-
tensin converting enzyme inhibitors in 24%, and aspirin in
86%. Lavie et al122 have documented increased use of these
newer treatments, noting that a greater proportion of patients
who undergo exercise testing after myocardial infarction tend
to have inferior infarcts and Q-wave infarcts, are older, and
have a greater functional capacity. It must also be realized that
a large percentage of postinfarction patients will not undergo
exercise testing due either to clinical instability or disabling
comorbidities, eg, unstable angina, uncontrolled heart failure,
uncontrolled arrhythmias, and neurological, orthopedic, or
vascular impairment of the lower extremities. In the largest
series to date, Gruppo Italiano per lo Studio della Sopravvi-
venza nell’Infarto Miocardico (GISSI-2) investigators123 have
reported that nearly 40% of the 10 219–patient cohort did not
undergo exercise testing within 28 days of myocardial infarc-
tion. This and several other studies in patients who have
received thrombolytic therapy126 and those who have not127–129
report that patients who are unable to perform an exercise test
have a much higher adverse event rate than those who are able.
With this background, the role of exercise testing after myo-
cardial infarction will be presented. The use of exercise or
pharmacological imaging studies (nuclear and echocardiogra-
phy) are not discussed here, as they are presented in detail in
the ACC/AHA guidelines for clinical use of cardiac radionu-
Figure 3. Strategies for exercise test evaluation soon after myocardial
infarction. If patients are at high risk for ischemic events, based on
clinical criteria, they should undergo invasive evaluation to determine
if they are candidates for coronary revascularization procedures (strat-
egy I). For patients initially deemed to be at low risk at the time of
discharge after myocardial infarction, two strategies for performing
exercise testing can be used. One is a symptom-limited exercise test at
14 to 21 days (strategy II). If the patient is on digoxin or if the baseline
electrocardiogram precludes accurate interpretation of ST-segment
changes (eg, baseline left bundle branch block or left ventricular
hypertrophy), then an initial exercise imaging study could be per-
formed. The results of exercise testing should be stratified to deter-
mine the need for additional invasive or exercise perfusion studies.
Another strategy (strategy III) is to perform a submaximal exercise test
at 4 to 7 days after myocardial infarction or just before hospital
discharge. The exercise test results could be stratified using the
guidelines in strategy I. If the exercise test studies are negative, a
second symptom-limited exercise test could be repeated at 3 to 6 weeks
for patients undergoing vigorous activity during leisure time activities,
at work, or exercise training as part of cardiac rehabilitation. The
extent of reversible ischemia on the exercise imaging study should be
considered before proceeding to cardiac catheterization. A small area
contiguous to the infarct zone may not necessarily require catheter-
ization. Modified from ACC/AHA guidelines.2
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clide imaging,5 guidelines for clinical application of echocardi-
ography,6 and guidelines for management of acute myocardial
infarction.2
Exercise testing after myocardial infarction yields informa-
tion in the following areas: (1) risk stratification and assess-
ment of prognosis; (2) functional capacity for activity pre-
scription after hospital discharge, including domestic and
occupational work evaluation and exercise training as part of
comprehensive cardiac risk reduction and rehabilitation; and
(3) assessment of adequacy of medical therapy and the need to
employ other diagnostic or treatment options.
Exercise Test Logistics
Exclusions From Testing The absolute and relative con-
traindications to exercise testing are presented in Table 1. In
patients with an abnormal resting ECG due to left bundle
branch block, preexcitation syndrome, LVH, digoxin therapy,
or those demonstrating major (greater than 1 mm) ST-segment
depression or elevation, an exercise or pharmacological imag-
ing study should be considered, as the accuracy of the exercise
ECG in detecting provokeable ischemia is reduced.
Timing and Protocol Exercise tests can be characterized
according to the time after myocardial infarction when the test
is performed and the protocol used. The timing of the predis-
charge exercise test continues to shorten, as does the hospital
stay for patients with an uncomplicated myocardial infarction.
Predischarge exercise tests in the recent literature range from
5 to 26 days after infarction.126,129–132 Exercise tests have been
performed as early as 3 days after myocardial infarction124;
however, the safety of this very early protocol has not been
established. Postdischarge tests have been performed early (14
to 21 days), at 6 weeks,133 or at 6 months after infarction.134
The exercise protocols can be either submaximal or symptom-
limited. Submaximal protocols have a predetermined end
point often defined as a peak heart rate of 120 bpm, or 70%
predicted maximum heart rate, or a peak MET level of 5.131
Symptom-limited tests are designed to continue until the
patient demonstrates signs and/or symptoms that necessitate
termination of exercise (ie, angina, fatigue, greater than or
equal to 2 mm of ST-segment depression, ventricular arrhyth-
mias, or greater than or equal to a 10 mm Hg drop in systolic
blood pressure from the resting blood pressure).135 The most
commonly used treadmill protocols are the modified Bruce,
the modified Naughton, and the standard Bruce.131 The ramp
treadmill or cycle ergometer protocols offer the advantage of
steady gradual increases in work rate and better estimation of
functional capacity136 but have not been widely studied in
patients early after myocardial infarction.
Recent studies have evaluated symptom-limited protocols
at 4 to 7 days after myocardial infarction and have included
patients treated with thrombolytic agents. These studies dem-
onstrate that such testing yields ischemic responses nearly
twice as often as submaximal tests and are a better estimate of
peak functional capacity.130,135,137 Thus, early symptom-limited
tests have the potential to be more useful in activity prescrip-
tion before discharge. However, the additive prognostic value
from information obtained from the performance of symptom-
limited protocols within days rather than weeks after myocar-
dial infarction has not yet been established.
Safety Exercise testing after myocardial infarction appears
to be safe. The incidence of fatal cardiac events, including fatal
myocardial infarction and cardiac rupture, is 0.03%, nonfatal
myocardial infarction and successfully resuscitated cardiac
arrest is 0.09%, and complex arrhythmias, including VT, is
1.4%. Symptom-limited protocols have an event rate which is
1.9 times that of submaximal tests, although the overall fatal
event rate is quite low.130,131,135 The majority of the safety data
are based on exercise testing performed more than 7 days after
myocardial infarction. The number of patients reported at 4 to
7 days is more limited, and typically time is reported as a mean
value or a range so that it is impossible to determine how many
patients were studied at 4 days.
Risk Stratification and Prognosis
The prognosis among survivors of myocardial infarction
continues to improve, particularly in patients who have re-
ceived thrombolytic therapy and revascularization during hos-
pitalization. One-year postdischarge mortality in the CAMI
study121 was 8.4% and was distinctly lower in the 45% of
patients who received thrombolytic therapy (3.7% mortality)
and in the 28% who underwent coronary angioplasty (3%
mortality) or coronary artery bypass surgery (3.7% mortality).
Data from the Global Utilization of Streptokinase and TPA
for Occluded Arteries (GUSTO) trial138 demonstrate that 57%
of the 41 021 patients who received thrombolytic therapy had
no complications (no recurrent ischemia, reinfarction, heart
failure, stroke, or invasive procedures) at 4 days after myocar-
dial infarction. The mortality rate at 1 month was 1% and at 1
year, 3.6%. Recurrent ischemia occurred in 7% of this group.
The improvement in 1-year mortality in patients who have
received thrombolytic therapy is multifactorial. Such patients
are (1) less likely to have severe three-vessel CAD; (2) have a
smaller infarct size; and (3) frequently undergo coronary
angiography in lieu of exercise testing. Consequently the
patient population that presently undergoes predischarge ex-
ercise testing in clinical trials of thrombolytic therapy is far
different from less selected historical populations or concur-
rent patient populations not treated with thrombolytic therapy.
Their low cardiac event rate following discharge is therefore
not surprising and substantially reduces the predictive accuracy
of early exercise testing.
There is limited evidence on the ability of exercise testing to
risk stratify patients who have not received reperfusion in the
current era. Although their subsequent mortality rates are
lower than in patients treated in the prethrombolytic era
because of therapeutic advances and revascularization, their
absolute event rates are higher than in patients who have
received thrombolytic therapy. Although the available evi-
dence is limited, exercise testing presumably can still assist in
the risk stratification of such patients.
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Inability to Exercise Data from GUSTO138 and other
large thrombolytic trials123,126 demonstrate that those pa-
tients unable to perform an exercise test have the highest
adverse cardiac event rate, while uncomplicated stable
patients have a low cardiac event rate even before under-
going further risk assessment by exercise testing. Earlier
studies in patients not receiving thrombolytic agents dem-
onstrate a similarly high event rate in those patients unable
to exercise.127,129 A comparison of selected studies is shown
in Tables 18 and 19.
Exercise-Induced Ischemia Some, but not all, studies per-
formed in the prethrombolytic era demonstrated that exercise-
induced ischemic ST-segment depression after myocardial
infarction was an important predictor of cardiac mortality.139–141
However, more recent studies are limited in that coronary
revascularization interventions are often performed in persons
who demonstrate an ischemic response,126,129,135,142,143 thus
reducing the predictive value of exercise-induced ischemia for
cardiac death or reinfarction.
Angiographic studies have demonstrated more multivessel
CAD in those with exercise-induced ischemia after myocardial
infarction compared with those without ischemia.144–146 The
GISSI-2 trial123 demonstrated that symptomatic but not silent
ischemic ST depression greater than or equal to 1 mm on
exercise testing at 28 days after myocardial infarction in
patients treated with thrombolytic therapy was an independent
predictor of cardiac mortality, but the absolute mortality of
such patients remains low (1.7%) by historical standards.
Other studies have shown only ST-segment depression greater
than 2 mm,147 ST depression at a low exercise level,148,149 or ST
depression among patients with controlled heart failure127 to
be independent predictors of death or nonfatal myocardial
infarction.
A recent meta-analysis (Table 18) that evaluated exercise
testing within 6 weeks of myocardial infarction demonstrates
the odds ratio for cardiac death among those with exercise-
induced ischemic ST-segment depression (greater than or
equal to 1 mm) to be 1.7 compared with those without such
ischemia. However, the positive predictive value of exercise-
induced ST depression for cardiac death or myocardial infarc-
tion at 1 year was found to be only 8% in patients treated with
thrombolytic agents versus 18% in those not treated with
thrombolytics.150
Exercise Capacity MET level or exercise duration achieved
on exercise testing is an important predictors of adverse
cardiac events after myocardial infarction.123,125,129,132,
134,143,148,149,151
This observation appears to hold true for tests performed
on the treadmill as well as the cycle ergometer. Failure to
achieve 5 METs during treadmill exercise is associated with a
worse prognosis.129,134,147,148
Blood Pressure Failure to increase systolic blood pressure
by 10 to 30 mm Hg during exercise testing has been shown to
be an independent predictor of adverse outcome in patients
after myocardial infarction.123,132,134,152,153 Inability to attain a
systolic blood pressure greater than 110 mm Hg predicted poor
outcome in patients with Q-wave infarcts129 but not among
those with non–Q-wave infarcts.127
Table 18. Meta-Analyses of Exercise Electrocardiographic Testing After Myocardial Infarction
Author
(Year)
Number of Patients Who
Underwent ETT
Number of
Patients
Treated With
Thrombolysis Type of Test
Timing
After MI
Length of
Follow-up Outcome
Froelicher141
(1987)
5331 Meta-analysis of 24
studies (1973–1986)
0 Treadmill or
cycle
1.6–9.0 wk 0.25–5.70 y Patients excluded from exercise testing had the highest
mortality.
Abnormal systolic blood pressure response and poor
exercise capacity were predictive of poor prognosis.
Submaximal or predischarge testing has greater
predictive power than postdischarge or maximal
testing.
Exercise-induced ST-segment depression is predictive
of increased risk only in patients with inferior-
posterior MI.
Shaw150
(1996)
15,613 Meta-analysis (28
studies of exercise-
10,067 Treadmill or
cycle
1–6 wk 1 y The odds ratio for cardiac death was significantly
higher for patients with:
ETT, 1980–1995)
● Exercise ST depression (or 1.7)
● Impaired systolic blood pressure (or 4.0)
● Limited exercise capacity (or 4.0)
The rate of cardiac death or MI in persons with
exercise-induced ST depression is lower in those
receiving thrombolytic therapy compared with those
without thrombolysis (8% vs 18%).
ETT indicates exercise treadmill testing, and MI, myocardial infarction.
283JACC Vol. 30, No. 1 GIBBONS ET AL.
July 1997:260–315 EXERCISE TESTING GUIDELINES
Other Variables Several studies demonstrate that the
occurrence of exercise-induced ischemia is similar in patients
with Q-wave and non–Q-wave infarctions.130,135,144,154–157 One
study found that exercise-induced ST segment depression in
patients with non–Q-wave myocardial infarction was associ-
ated with greater risk of cardiac death than that of ST
depression in patients with Q-wave infarction.158 The use of
b-adrenergic blocking agents after myocardial infarction has
increased over the past decade. They are used in the treatment
of acute ischemia and arrhythmia and for their effect in
reducing early and late mortality after infarction.2 Thus, the
number of patients taking these agents at the time of the
postinfarction exercise test continues to grow.122 b-Adrenergic
blockers reduce the occurrence of angina and ischemic ST
changes and lengthen the time to ischemia on exercise test-
ing.128,159–161 Although b-adrenergic blockade attenuates the
ischemic response, two long-term follow-up studies have dem-
onstrated that these agents do not interfere with poor func-
tional capacity as a marker of adverse prognosis.128,161 Patients
taking b-blockers after myocardial infarction should continue
to do so at the time of exercise testing. Because patients will be
taking these medications for an indefinite period after infarc-
tion, the exercise test response while patients are taking
b-blockers provides information about the adequacy of medi-
Table 19. Selected Studies* of Exercise Testing After Myocardial Infarction in the Thrombolytic Era
Author (Year)
Number of
Patients Who
Underwent
ETT
Number of
Patients
Treated With
Thrombolysis Type of Test
Timing
After MI
Length of
Follow-up Outcome
Villella123 (1995) 6296 6296 Symptom-limited 28 d 6 mo ● 7.1% mortality in those unable to exercise
GISSI-2 study ● 1.7% mortality in those with a positive test
result
● 0.9% mortality in those with negative test
results
● Predictors of mortality:
— Angina 1 $1 mm ST?
— ST 2$1 mm at ,100 W or ,6 min
exercise
— ,6 min exercise or peak work rate
,100 W
— SBP rise ,28 mm Hg from rest
Chaitman126 (1993)
TIMI-2 Study
2502 2502 Submaximal 2 wk 1 y ● 1261 who underwent ETT were randomly
assigned to conservative strategy
● 9.3% mortality in those unable to exercise
vs 2.3% in those who underwent ETT
● 2.4% mortality with exercise ST2 vs 0.6%
without (P 5 .13)
● 9.3% underwent revascularization before
discharge
Stevenson148 256 256 Symptom-limited 7–21 d 10 mo ● Predictors of recurrent ischemia:
(1993) (6–12 mo) — ST segment 2$1 mm
— Exercise tolerance ,7 METs
Arnold153 (1993) 981 490 Symptom-limited Predischarge 1 y ● 260 of 981 subjects were randomly
assigned to receive immediate PTCA
● 3.6 relative risk of mortality in those
unable to exercise
● Exercise test predictors of mortality:
— SBP rise ,30 mm Hg from rest
Mickley157 (1993) 123 35 Symptom-limited 1.4 wk 1 y ● ST depression .1 mm predicted future
angina but not reinfarction or death
Piccalo`169 (1992) 157 157 Symptom-limited 15 d 6 mo ● 30% of patients with positive exercise test
underwent coronary revascularization
● 90% of patients without angina or
ST2$1 mm had no cardiac events in
follow-up
*Selected studies were derived from a MEDLINE search of reports from 1980 to 1995 of all studies that presented a separate analysis to evaluate predischarge
exercise-electrocardiographic testing and included patients (some or all) who have received thrombolytic therapy. Studies in which exercise imaging variables were
entered into multivariate analysis were excluded. ETT indicates exercise electrocardiographic testing; MI, myocardial infarction; GISSI-2, Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico 2 Trial; SBP, systolic blood pressure; TIMI-2, Thrombolysis in Myocardial Infarction II Trial; METs, metabolic equivalents;
and PTCA, percutaneous transluminal coronary angiography. Modified from ACC/AHA guidelines.2
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cal therapy in preventing ischemia and arrhythmias as well as
controlling heart rate and blood pressure response during
exercise.
Activity Counseling
Exercise testing after myocardial infarction is useful for
counseling patients and their families about domestic, recre-
ational, and occupational activities that can be safely per-
formed after discharge from the hospital. Functional capacity
in METs derived from the exercise test can be used to estimate
tolerance for specific activities. Published charts that provide
an estimate of energy requirements for various activities are
available7 but should be used only as a guide, with the
knowledge that the intensity at which activities are performed
will directly influence the amount of energy required. Most
domestic chores and activities require less than 5 METs;
hence, a submaximal test at the time of hospital discharge can
be useful in counseling regarding the first several weeks after
myocardial infarction.
The follow-up symptom-limited testing performed 3 to 6
weeks after myocardial infarction can assist in further activity
prescription and issues concerning return to work. Most occu-
pational activities require less than 5 METs. In the 15% of
persons in the labor force whose work involves heavy manual
labor,162 the exercise test data should not be used as the sole
criterion for recommendations regarding return to work. En-
ergy demands for lifting heavy objects, temperature, and
environmental and psychological stresses are not assessed by
routine exercise tests and must be taken into consideration.
Simulated work tests can be performed in patients with low
functional capacity, left ventricular dysfunction, exercise-
induced ischemia, and those who are otherwise apprehensive
about returning to a physically demanding occupation.163–165
Cardiac Rehabilitation
Cardiac rehabilitation combines prescriptive exercise train-
ing with coronary risk factor modification in patients with heart
disease. It is considered standard care that should be integrated
into the treatment plan of patients with CAD.166 Randomized
trials of cardiac rehabilitation after myocardial infarction show
consistent trends toward survival benefit among patients enrolled
in cardiac rehabilitation programs.162,166 Meta-analyses of these
trials have calculated a significant 20% to 25% reduction in
cardiovascular death in patients enrolled in such programs.167
Moreover, higher levels of physical fitness when measured on an
exercise tolerance test are associated with reduced subsequent
mortality.123,129,132,134,143,148,149,151 Exercise training improves ex-
ercise capacity among cardiac patients by 11% to 66% after 3 to
6 months of training, with the greatest benefits among those who
are most unfit.166
Exercise testing in cardiac rehabilitation is essential in
development of the exercise prescription to establish a safe and
effective training intensity, in risk stratification of patients to
determine the level of supervision and monitoring required
during exercise training sessions, and in evaluation of training
program outcome.7,164,168 For these reasons, symptom-limited
exercise testing before program initiation is needed for all
patients in whom cardiac rehabilitation is recommended (re-
cent myocardial infarction, recent coronary artery bypass sur-
gery, recent coronary angioplasty, chronic stable angina, con-
trolled heart failure).7,166
Exercise testing in the stable cardiac patient who continues
an exercise training program is often performed after the
initial 8 to 12 weeks of exercise training and periodically
thereafter, although there are no available studies to assess its
value. Such testing may be useful to rewrite the exercise
prescription, evaluate improvement in functional capacity, and
provide feedback to the patient.166
Summary
Contemporary treatment of the patient with acute myocar-
dial infarction includes one or more of the following: medical
therapy, thrombolytic agents, and coronary revascularization.
These interventions have led to marked improvement in the
prognosis of the postinfarction patient, particularly those who
have been treated with reperfusion. The patient population
eligible for predischarge exercise testing in clinical trials of
thrombolytic therapy is therefore far different from less selected
historical populations. Their low cardiac event rate substantially
reduces the predictive accuracy of early exercise testing. However,
there is limited evidence on the ability of exercise testing to risk
stratify patients who have not received reperfusion therapy in the
current era. Their mortality rates are higher than those who
received either thrombolytic therapy or who have undergone
coronary revascularization. Thus, exercise testing presumably can
still assist in risk stratification of such patients. Patients who have
not undergone coronary revascularization and are unable to
undergo exercise testing have the worst prognosis.
Exercise testing after myocardial infarction is safe. Sub-
maximal testing can be performed at about 4 to 7 days; about
3 to 6 weeks later a symptom-limited exercise test can be
performed. Alternatively, symptom-limited tests can be con-
ducted early after discharge at about 14 to 21 days. Strategies
for exercise test evaluation after myocardial infarction are
outlined in Fig 3.3
Exercise test predictors of adverse outcome in the postin-
farction patient include ischemic ST-segment depression greater
than or equal to 1 mm, particularly if accompanied by symptoms,
at a low level of exercise, or in the presence of controlled heart
failure; functional capacity less than 5 METs; inadequate blood
pressure response (peak systolic blood pressure less than
110 mm Hg or less than 30 mm increase from resting level).
Exercise testing is useful in activity counseling after dis-
charge from the hospital. Exercise testing is also an important
tool in exercise training as part of comprehensive cardiac
rehabilitation. It is used to develop and modify the exercise
prescription and assess the patient’s response to and progress
in the exercise training program.
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V. Exercise Testing Using Ventilatory
Gas Analysis
Class I
1. Evaluation of exercise capacity and response to therapy in
patients with heart failure who are being considered for
heart transplantation.
2. Assistance in the differentiation of cardiac versus pulmo-
nary limitations as a cause of exercise-induced dyspnea or
impaired exercise capacity when the cause is uncertain.
Class IIa
1. Evaluation of exercise capacity when indicated for medical
reasons in patients in whom subjective assessment of max-
imal exercise is unreliable.
Class IIb
1. Evaluation of the patient’s response to specific therapeutic
interventions in which improvement of exercise tolerance is
an important goal or end point.
2. Determination of the intensity for exercise training as part
of comprehensive cardiac rehabilitation.
Class III
1. Routine use to evaluate exercise capacity.
Ventilatory gas exchange analysis during exercise testing is
a useful adjunctive tool in assessment of patients with cardio-
vascular and pulmonary disease. Measures of gas exchange
primarily include oxygen uptake (VO2), carbon dioxide output
(VCO2), minute ventilation, and ventilatory/anaerobic thresh-
old. VO2 at maximal exercise is considered the best index of
aerobic capacity and cardiorespiratory function. Maximal VO2
is defined as the point at which no further increase in measured
VO2 occurs despite an increase in work rate (a plateau is
reached) during graded exercise testing. Peak VO2 is the
highest VO2 attained during graded exercise testing, but the
term does not imply that a plateau in measured VO2 is reached.
Most clinical studies report peak VO2 rather than maximal
VO2, as the latter is often difficult to determine precisely.
Estimation of peak aerobic capacity using published formulas
without direct measurement is limited by physiological and
methodological inaccuracies. This is illustrated in Fig 4, which
demonstrates the wide scatter of measured VO2 per given
treadmill time on a progressive treadmill protocol. Exercise
protocols with large increments in work rate per stage136 (Fig
5), the use of handrail support during treadmill exercise,170 and
the application of a single regression formula to a wide variety
of heterogeneous populations,171 which range from the ex-
tremely fit to those impaired by heart or lung disease, all limit
the reliability of VO2 estimates. However, direct measures of
VO2 are reliable and reproducible and provide the most
accurate assessment of functional capacity.172 Gas exchange
data can provide important information to evaluate functional
capacity and distinguish cardiovascular from pulmonary limi-
tations during exercise.
The measurement of gas exchange variables has been
simplified in recent years with the development of rapid gas
analyzers for oxygen and carbon dioxide and computerized
on-line analysis systems. In addition to peak or maximal VO2,
other valuable measures can be obtained. Minute ventilation and
its relation to carbon dioxide production and oxygen consumption
yield useful parameters of cardiac and pulmonary function. The
respiratory exchange ratio (RER) represents the amount of
carbon dioxide produced divided by the amount of oxygen
consumed. The RER generally ranges from 0.7 to 0.85 at rest and
is partly dependent on the predominant fuel used for cellular
metabolism. At high levels of exercise, CO2 production exceeds
VO2, and thus an RER greater than 1.0 often indicates that the
subject is giving a maximal level of effort.
Another index of relative work effort is the ventilatory/
anaerobic threshold (VAT). This is a highly reproducible point
during exercise at which ventilation abruptly increases despite
Figure 4. Relation of treadmill time (independent of specific protocol)
to measured oxygen uptake using a progressive treadmill protocol.
From Froelicher et al174 with permission.
Figure 5. Relation between measured versus predicted oxygen uptake
for the Bruce protocol and progressive ramp protocol in patients with
heart failure. Unity is achieved when predicted oxygen uptake is equal
to measured oxygen uptake. CHF indicates congestive heart failure.
From Froelicher et al174 with permission.
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linear increases in work rate. Shortly beyond the anaerobic
threshold, fatigue usually ensues. The term anaerobic thresh-
old is based on the hypothesis that at a given work rate, the
oxygen supplied to exercising muscles does not meet the
oxygen requirements. This imbalance increases anaerobic gly-
colysis for energy generation, yielding lactate as a metabolic
byproduct.173 Although the anaerobic threshold is a defined
end point that can be established by several different methods,
the actual cause of the observed abrupt rise in minute venti-
lation remains controversial. This hypothesis is supported by
the fact that measured lactate levels increase at the point at
which minute ventilation begins its curvilinear relation to work
rate. However, whether muscle hypoxia is a main stimulus for
increased lactate production is not yet clear. Thus, the true
anaerobic threshold at the muscle cell level, the onset of blood
lactate accumulation, and the VAT are separate but related
events that occur during exercise.
The VAT is determined by several easily recognized mea-
surements that can be obtained during respiratory gas analysis.
These include (1) a departure of linearity of minute ventilation
(VE) and VCO2 with increasing work rates and an abrupt
increase in the RER and fraction of O2 in expired air (FEO2);
(2) an increase in VE/VO2 without an increase in VE/VCO2, and
an increase in FEO2 without a decrease in the fraction of CO2 in
expired air; (3) the lowest VE/VO2 value measured during
exercise; and (4) a curvilinear increase in VE and VCO2 with a
linear increase in VO2 (Fig 6).173,174 Further details on the
methodology and interpretation of data obtained during ven-
tilatory gas analysis are available.8,174,175
Measurement of expiratory gases during exercise testing
can (1) provide the best estimate of functional capacity; (2)
grade the severity of functional impairment; (3) objectively
evaluate the response to interventions that may affect exercise
capacity; (4) objectively track the progression of disease that
may limit exercise capacity; and (5) assist in differentiating
cardiac from pulmonary limitations in exercise capacity.176
Normal values for maximal oxygen uptake among healthy
adults at different ages are available7 and may serve as a useful
reference in the evaluation of exercise capacity. The VAT has
been proposed as a more sensitive index of fitness than maximal
VO2, heart rate, or total fitness in children. Normal values for
VAT in children are provided elsewhere.9 Determination of
exercise training intensity to maintain or improve health and
fitness among persons with or without heart disease can be
derived from direct measurements of peak oxygen consumption
as shown in Table 20.177 This may be most useful when the heart
rate response to exercise is not a reliable indicator of exercise
intensity (eg, patients with fixed-rate pacemakers). Rating of
perceived exertion is also helpful in this setting.
Data derived from exercise testing with ventilatory gas
analysis have proved to be reliable and important measures in
the evaluation of patients with heart failure.178–181 The exercise
capacity of patients with heart failure based on their peak VO2
and VAT can be divided into four classes as shown in Table
21.182 This classification system is limited in that age and
gender are not taken into account. Moreover, peak exercise
capacity does not necessarily reflect the daily activities of heart
failure patients. Stratification of ambulatory heart failure
patients using this technique has improved ability to identify
those with the poorest prognosis, who should be considered for
heart transplantation.183,184 (See Table 22.)
The technique of ventilatory gas measurement has a num-
ber of potential limitations that hinder its broad applicability.
Gas exchange measurement systems are costly and require me-
ticulous maintenance and calibration for optimal use.170 Person-
nel who administer tests and interpret results must be trained and
proficient in this technique. Finally, the test requires additional
cost and time as well as patient cooperation.8
VI. Special Groups: Women, Asymptomatic
Individuals, and Postrevascularization Patients
Women
Rationale Cardiovascular disease is one of the principal
causes of death in women, exceeding mortality due to breast
cancer by a factor of 11.185 The probability of coronary disease
in women, based on age, gender, and the nature of symp-
toms,17 is most commonly in the low to intermediate probabil-
ity range, especially in premenopausal women. While typical
angina is as meaningful in women older than 60 years as in
men,186 the clinical diagnosis of coronary disease in women
may be difficult to make: almost half the women with anginal
symptoms in the Coronary Artery Surgery Study (CASS)187
(who were younger than 65) had normal coronary arterio-
grams. From a Bayesian standpoint, the low prevalence of
CAD presents a particularly difficult situation for noninvasive
testing. Moreover, the results of functional testing—exercise
capacity, ST-segment changes, and imaging tests—may be
influenced by gender.
Accuracy of Electrocardiographic Analysis in Women. The
ST response to exercise appears to be gender-related from an
early age, with ST-segment abnormalities more commonly
reported in third-grade girls than boys.188 Studies examining
the accuracy of ST-segment interpretation for the diagnosis of
coronary disease according to gender are summarized in Table
23.84,88,186,189–192,194–199 Variations in results in women may be
due to the use of different criteria for defining coronary
disease, differences in population selection (including preva-
lence of prior myocardial infarction and multivessel disease),
and differences in performance of the test, including criteria
for ST-segment positivity, and type of exercise.
Exercise-induced ST depression is less sensitive in women
than men,84 reflecting a lower prevalence of severe CAD and
the inability of many women to exercise to maximum aerobic
capacity.201,202 The exercise ECG is commonly viewed as less
specific in women than men, although Table 23 demonstrates
that this finding has not been uniform. Even after patients with
referral bias were excluded, the ST-segment response was
found to be less accurate in women.28 Significant gender
differences were reported in unbiased estimates of sensitivity
and specificity. However, these were modest (less than 10%),
287JACC Vol. 30, No. 1 GIBBONS ET AL.
July 1997:260–315 EXERCISE TESTING GUIDELINES
and did not appear to preclude the use of treadmill exercise
testing in women.28 A careful analysis of the incremental
diagnostic value of treadmill testing found similar value in men
and women.200 Studies that have documented lower specificity
in women have cited both lower disease prevalence and
non-Bayesian factors,192 which might include the greater prev-
alence of mitral valve prolapse and syndrome X in women,
differences in microvascular function (leading perhaps to cor-
onary spasm), and possibly hormonal differences.
The standard approach to exercise testing involves catego-
rization of the ST-segment response as “positive” or “nega-
tive” results. The accuracy of exercise testing in women may be
enhanced by attention to features other than the absolute level
of ST depression. The ST/heart-rate relation has recently been
shown to be of value203 but awaits widespread application.
Avoidance of identifying ST depression in the inferior leads
and identification of test positivity based on persistent
changes204 enhance the predictive value of a positive test but
may compromise the predictive value of a negative test.
Finally, as the ST-segment response is a continuous variable,
continuous analysis of the ST segment may recover the infor-
mation lost from its analysis as a dichotomous variable. This
analysis has been combined with non-ECG end points into
multivariate models (see below).
Non-ECG End Points. The exercise test provides a wealth
of other material, including exercise capacity, hemodynamic
response to exercise, and the presence of cardiac symptoms,
which are used in interpretation of the test result and are not
apparent in ST analysis alone. The diagnostic contribution of
these findings has been calculated in multivariate models,
resulting in development of equations giving the likelihood of
disease. The accuracy of exercise testing was significantly
Figure 6. Measurements used to determine the gas exchange anaero-
bic threshold (Atge). VE indicates minute ventilation; VCO2, carbon
dioxide production; VO2, oxygen uptake; and FeO2, fraction of expired
air that is oxygen. From Froelicher et al174 with permission.
Table 20. Classification of Exercise Intensity Based on
Oxygen Uptake177
Intensity % VO2max
Very light , 25
Light 25–44
Moderate 45–59
Hard 60–84
Very hard $ 85
Maximal 100
VO2max indicates maximal oxygen uptake.
Table 21. Classification of Exercise Capacity in Patients With
Heart Failure, Based on Peak Oxygen Uptake and Ventilatory
Anaerobic Threshold182
Class Impairment
Peak VO2
(mL/kg/min)
VAT
(mL/kg/min)
A None to mild . 20 . 14
B Mild to moderate 16–20 11–14
C Moderate to severe 10–16 8–11
D Severe , 10 , 8
VO2 indicates oxygen uptake; and VAT, ventilatory anaerobic threshold.
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increased by the use of a multivariate model compared with
ST-segment evaluation alone.196 However, not all centers have
reported these favorable findings,198 and although the exercise
score concept is attractive, its clinical application in women has
remained limited.
Conclusion. The diagnosis of CAD in women presents
difficulties that are not experienced in the investigation of men.
These problems reflect differences in exercise physiology, body
habitus, coronary physiology, and prevalence of CAD between
men and women.
The accuracy of the exercise ECG for diagnosis of coronary
disease in women may have important limitations. Physicians
must be cognizant of the influence of submaximal exercise on
sensitivity; patients likely to exercise submaximally should
undergo pharmacological stress testing. Concern about false-
positive ST-segment responses may be addressed by careful
assessment of posttest probability and selective use of stress
imaging tests before proceeding to angiography.88 On the
other hand, the difficulties posed by clinical evaluation of
probability of CAD in women have led to speculation that
stress imaging approaches may be an efficient initial alternative
to the exercise ECG in women.199 Although the optimal
strategy for circumventing false-positive test results for diag-
nosis of CAD in women remains to be defined, there are
currently insufficient data to justify routine stress imaging tests
as the initial test for CAD in women.
Diagnosis of Coronary Artery Disease in the Elderly
Rationale Patients older than 65 years are usually defined
as “elderly.” One possible subdivision of this group205 is the
“young old” (65 to 75 years) and the “old old” (older than 75);
CAD is highly prevalent in symptomatic patients in both
groups. With the aging of the population, the former now
constitute a substantial proportion of patients; thus, this sec-
tion focuses on patients older than 75 years. Unfortunately,
few data have been published with respect to the use of
exercise testing for diagnostic and prognostic assessment of
CAD in this group. For example, tables used for the identifi-
cation of pretest disease probability do not consider patients
older than 70, and scores for assessing prognosis have not
included elderly patients. Presumably the prevalence and risk
of coronary disease increase with advancing age, but nonethe-
less, in 1989 the National Health Interview Survey206 reported
that the prevalence of diagnosed CAD was 1.8% in men over
the age of 75 and 1.5% in women over 75. This disease is
commonly occult, silent ischemia being estimated to be present
in 15% of 80-year-olds.207 On Bayesian grounds, the high
prevalence and greater severity of coronary stenoses in this
group increase the sensitivity of testing but make it harder to
rule out significant disease.
The performance of exercise testing poses several problems
in the elderly, but it is certainly not contraindicated in this
group. Functional capacity is often compromised due to mus-
cle weakness and deconditioning, and therefore the decision
whether to send the patient for an exercise or pharmacological
stress test is more important than in younger patients. In some
patients with problems of gait and coordination, a bicycle
exercise test may be more attractive than a treadmill exercise
Table 22. Guidelines for Peak Exercise Oxygen Uptake as a
Criterion for Cardiac Transplantation184
Category for
Transplant
Peak VO2
(mL/kg/min)
Accepted indication , 10
Probable indication , 14
Inadequate indication . 15
VO2 indicates oxygen uptake.
Table 23. Sensitivity and Specificity of Exercise Electrocardiography in Women*
Author (year)
n
(Women)
Mean Age
(y)
Definition of
CAD
Multivessel
CAD (%)
Positive
Exercise Test
Result (% of
Women)
Sensitivity: Women
(n 5 Patients
With CAD)
Specificity: Women
(n 5 Patients
Without CAD)
Guiteras189 (1972) 112 49 . 70% dia 12 38 79%, n 5 42 66%, n 5 70
Linhart190 (1974) 98 46 . 50% dia na 34 71%, n 5 24 78%, n 5 74
Sketch191 (1975) 56 50 . 75% dia na 27 50%, n 5 10 78%, n 5 46
Barolsky192 (1979) 92 50 . 50% dia 16 41 60%, n 5 30 68%, n 5 62
Weiner193 (1979) 580 na . 70% dia 16 48 76%, n 5 169 64%, n 5 411
Ilsley194 (1982) 62 51 . 50% dia 27 44 67%, n 5 27 74%, n 5 35
Hung195 (1984) 92 51 . 70% dia 16 51 75%, n 5 28 59%, n 5 64
Hlatky84 (1984) 613 na . 75% dia na na 57%, n 5 194 86%, n 5 419
Melin88 (1985) 93 51 . 50% dia 20 30 58%, n 5 24 80%, n 5 69
Robert196 (1991) 135 53 . 50% dia 29 37 68%, n 5 56 48%, n 5 79
Chae197 (1993) 114 na . 50% dia na 54 66%, n 5 71 60%, n 5 43
Williams198 (1994) 70 60 . 50% dia 19 57 67%, n 5 33 51%, n 5 37
Marwick199 (1995) 118 60 . 50% dia 17 58 77%, n 5 48 56%, n 5 70
Morise200 (1995)† 264 56 . 50% dia 27 33 46%, n 5 81 74%, n 5 151
Morise200 (1995)‡ 288 57 . 50% dia 26 36 55%, n 5 106 74%, n 5 159
*Studies of .50 women. †Derivation set. ‡Validation set. CAD indicates coronary artery disease; dia, diameter stenosis; and na, not available.
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test,208 but in older patients, bicycle exercise is often limited by
unfamiliarity. Certainly, if treadmill exercise is used, more
attention must be given to the mechanical hazards of exercise
in elderly patients. More gradual protocols should be favored
in selection of a treadmill exercise protocol in elderly pa-
tients.209 Elderly patients are much more likely to hold on to
the handrails tightly, reducing the validity of treadmill time for
estimating METs.
Interpretation of exercise testing in the elderly differs
slightly from that in the young. Resting ECG abnormalities,
including prior myocardial infarction and intraventricular con-
duction delays, may compromise the availability of diagnostic
data from the ECG. Nonetheless, the application of standard
ST-segment response criteria to elderly subjects is not associ-
ated with significantly different accuracy from younger peo-
ple.84 Due to the greater prevalence of both CAD and severe
CAD, it is not surprising that the exercise ECG in this group
has a slightly higher sensitivity (84%) and lower specificity
(70%) than in younger patients.210 These false-positive results
may also reflect the coexistence of LVH due to valvular disease
and hypertension as well as conduction disturbances. Although
the risk of coronary angiography may be greater in the elderly
and the justification for coronary intervention may be less, the
results of exercise testing in the elderly remain important,
because medical therapy may itself carry risks in this group.
In addition to ST-segment criteria, attention should be paid
to chronotropic and inotropic responses to exercise, exercise-
induced arrhythmias, and exercise capacity. Arrhythmias occur
more frequently with increasing age, especially at higher
workloads but are not necessarily an adverse feature unless
associated with evidence of ischemia.209 Chronotropic incom-
petence (failure to achieve 85% of age-predicted maximum
heart rate) and a hypotensive response to exercise are ominous
features, as shown in other age groups. The presence of ST
depression in asymptomatic elderly patients is not associated
with high event rates,211 and the positive predictive value of
these features may be enhanced by consideration of other
exercise parameters as well as a stepwise approach combined
with stress imaging tests, discussed in the section on screening.
Exercise Testing in Asymptomatic Persons Without
Known Coronary Artery Disease
Class I
1. None.
Class IIb
1. Evaluation of persons with multiple risk factors.*
2. Evaluation of asymptomatic men older than 40 years and
women older than 50 years:
● Who plan to start vigorous exercise (especially if seden-
tary)
or
● Who are involved in occupations in which impairment
might impact public safety
or
● Who are at high risk for CAD due to other diseases (eg,
chronic renal failure)
Class III
1. Routine screening of asymptomatic men or women.
Rationale Background. Studies of the natural history of
CAD have shown early changes of atherosclerosis to be
prominent in young, presumably asymptomatic military per-
sonnel and civilians dying from other causes.214 CAD is
responsible for over half a million deaths each year and 1.5
million hospitalizations for myocardial infarction, at a cost of
more than $100 billion a year in the United States.185 In light
of these human and economic costs, attention has turned to
the early diagnosis of CAD in the hope that treatment may
avoid complications and reduce the cost of acute treatment.
The purpose of screening is to either prolong life or
improve its quality because of early detection of disease.215 In
asymptomatic patients with severe coronary disease, data from
the CASS and the Asymptomatic Cardiac Ischemia Pilot
(ACIP) study suggest that revascularization may prolong
life.216,217 However, the ACIP was a pilot study, and an NHLBI
follow-up study has suggested that acute cardiac events in
predominantly low-risk patients are unpredictable.218 Diagno-
sis of ischemia may stratify patients for the intensity of risk
factor modification.219 Although this may seem inconsistent
with the current position that simple risk reduction should be
attempted in all patients,220 the identification of functional
impairment may motivate patients to be more compliant with
risk factor modification.113
On the other hand, the use of exercise testing to screen for
CAD poses problems from standpoints of both positive and
negative predictive value. First, because these tests are used for
the diagnosis of coronary disease in asymptomatic persons,
mild coronary disease, which is prognostically benign, may be
identified. Conversely, because many coronary events occur
due to plaque rupture involving minor stenoses, the absence of
flow-limiting stenoses (associated with a negative exercise test)
does not preclude the occurrence of subsequent myocardial
infarction.
Diagnostic Considerations. As discussed earlier, the posttest
probability of coronary disease is dependent on the accuracy of
the test and the pretest probability of disease. Unfortunately,
the accuracy of exercise testing in asymptomatic persons has
never been defined and probably never will be, because these
persons could not undergo angiography. An alternative, obser-
vational approach involves analysis of the predictive value of a
*Multiple risk factors are defined212 as hypercholesterolemia (greater than
240 mg/dL), hypertension (systolic blood pressure greater than 140 mm Hg or
diastolic blood pressure greater than 90 mm Hg), smoking, diabetes, and family
history of heart attack or sudden cardiac death in a first-degree relative younger
than 60 years. An alternative approach might be to select patients with a
Framingham risk score consistent with at least a moderate risk of serious cardiac
events within 5 years.213
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positive test, which has ranged between 25%221 and 72%.222
These numbers are obviously influenced by work-up bias.
Nonetheless, the predictive value of a positive test may be
enhanced by consideration of not only the ST-segment re-
sponse but also other exercise variables,223 although attempts
to enhance the predictive value of a positive test usually
compromise the predictive value of a negative test. Nonethe-
less, additional risk stratification is possible by taking into
account the severity of ST-segment depression and blood
pressure response to exercise.224
Prognostic Evaluation. Despite these observations, the real
issue is not to identify coronary disease but to predict outcome.
Traditionally the prediction of myocardial infarction and death
are considered the most important end points of screening,
although these have been addressed in only the Seattle Heart
Watch,212 the Multiple Risk Factor Intervention Trial
(MRFIT),225 and Lipid Research Clinics (LRC)226 studies.
Angina is a less important end point, because intervention can
be postponed until its onset without harming the patient. In
addition, the use of angina as an end point has a methodolog-
ical weakness, because the presence of a previous positive
exercise test may make it more likely that chest pain symptoms
are interpreted as anginal. Nonetheless, in the era of managed
care, the likelihood of re-presentation with progressive symp-
toms may carry important cost implications, and for this reason
other studies using a composite end point including angina
have been included in Table 24.212,225–227,230,232,233 In general,
the relative risk of a subsequent event is increased in patients
with a positive exercise test result, although the absolute risk of
a cardiac event in an asymptomatic population remains in only
the 1% range,225 even if ST changes are associated with risk
factors. A positive exercise test result is more predictive of
later development of angina than occurrence of a major event.
Even taking all end points (including subsequent angina) into
account, a minority of patients with a positive test result
experience cardiac events, but those with a positive test result
may suffer from being labeled at risk, as they may undergo
unnecessary, expensive, and potentially hazardous interven-
tions.
Furthermore, most patients with subsequent cardiovascular
death have a negative test result, because the sensitivity for
detecting subsequent cardiovascular death is low. Because of
the role of false-positive test results, several studies have
recommended consideration of other data complementary to
the presence of greater than 1 mm of ST-segment depression.
Taking other factors into account in a multivariate analysis has
shown exercise testing to be predictive of hard events,225,226,232
with relative risks in the range of 4:1 or 5:1. These include
other aspects of the ST-segment response, other exercise
parameters, risk factors, and the results of stress-imaging tests.
ST-SEGMENT RESPONSE. More recent studies have replaced
or supplemented use of greater than 0.1 mV of ST-segment
depression with the ST integral225,226 and the ST heart rate
slope. The latter was predictive of outcome despite the fact
that ST-segment analysis alone was not predictive of outcome
in the Framingham study.232
EXERCISE CAPACITY. Interestingly there appears to be no
relation between the performance of maximal or submaximal
testing and the predictive value of the ST-segment response.
However, the development of evidence of ischemia at low work
load is associated with a relatively high risk of subsequent
events. ST-segment depression occurring after fewer than 6
minutes of the Bruce protocol has been associated with a
relative risk of 6.7 in men and 3.6 in women,212,226 and ischemia
at less than 5 minutes of exercise has been associated with a
relative risk of 14.7 in men and 5.6 in women.230
RISK FACTORS. The Bayesian issues posed by testing patients
with a low probability of CAD may be reduced a little by
screening a slightly higher-risk group. This can be done by
applying the test only to patients with risk factors for CAD (see
next section).
STRESS IMAGING TESTS. Recently exercise testing was shown
to be of value for screening patients with a family history of
coronary disease. This study used a composite end point rather
than hard events, and the addition of thallium imaging to the
exercise test substantially increased the predictive value of the
exercise data alone.234
Who to Screen? POPULATION SCREENING. General screening
programs, for example, attempting to identify young patients
with early disease, have the limitation that severe CAD
(requiring intervention) in asymptomatic patients is exceed-
ingly rare.17 Although the physical risks of exercise testing are
negligible,7 false-positive test results may engender inappro-
priate anxiety and may have serious adverse consequences in
relation to work and insurance. For these reasons, the use of
exercise testing in healthy asymptomatic persons has not been
recommended.235,236
SCREENING IN PATIENTS WITH CORONARY ARTERY DISEASE RISK
FACTORS. The importance of accounting for the clinical situa-
tion of patients with a positive test result was best illustrated in
the Seattle Heart Watch Study.212 In this study the results of
exercise testing were not predictive of outcome in the group as
a whole, but in patients with one or more risk factors and two
abnormal features on exercise testing (chest pain, exercise less
than 6 minutes, attainment of less than 90% of predicted heart
rate, or ST-segment depression), there was a 30-fold increment
of cardiac risk, even though this group accounted for a small
fraction (less than 10%) of the study population. Similarly, in
the MRFIT study, although the intervention group showed
only a trend to more favorable outcome compared with the
usual care group, patients with a positive exercise test result
significantly benefited by risk factor modification.237
Based on prognostic considerations, asymptomatic male
patients older than 40 years with one or more risk factors
(hypercholesterolemia, hypertension, smoking, diabetes, or
family history of premature CAD) may obtain useful prognos-
tic information from exercise testing. The greater the number
of risk factors (ie, pretest probability), the more likely the
patient will profit from screening. For these purposes, risk
factors should be strictly defined: hypercholesterolemia as total
cholesterol greater than 240 mg/dL, hypertension as systolic
blood pressure greater than 140 mm Hg or diastolic blood
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pressure greater than 90 mm Hg, smoking, diabetes, history of
heart attack or sudden cardiac death in a first-degree relative
less than 60 years old. An alternative approach would be to
study patients with a certain level of cardiovascular risk
expressed as a continuous variable and therefore accounting
for not only the presence but also the severity of risk factors.
Such data have been derived in asymptomatic persons from the
Framingham study.213 Attempts to extend screening to persons
with lower degrees of risk are not recommended, as screening
is unlikely to improve patient outcome.
SCREENING IN OTHER PATIENT GROUPS AT HIGH RISK OF
CORONARY ARTERY DISEASE. Some patient subgroups are
known to be at particularly high risk of coronary disease and
are often asymptomatic in the presence of this disease. In
addition to patients with diabetes and peripheral vascular
disease,238 they include persons with previous cardiac trans-
plantation239 and chronic renal failure.240 These patients are
more likely to have established coronary disease requiring
intervention. Unfortunately, however, partly because of the
prevalence of coexisting LVH, functional testing is often
nondiagnostic, and standard noninvasive tests have proved
particularly insensitive for detection of coronary artery vascu-
lopathy after cardiac transplantation.241 In these groups, stress
imaging tests may be of more value for risk stratification.
BEFORE FITNESS PROGRAM. A distinction must be made
between asymptomatic patients with and without a history of
cardiac disease. Many asymptomatic patients presenting for
advice about becoming fit are doing so because of the devel-
opment of symptoms that they either deny or ascribe to
noncardiac causes. Although small, the risk of sudden death
during exercise in patients with cardiac disease (which has
been estimated at 1 per 784 000 hours) is higher than that of
the general population.242 In those with a history of cardiac
disease (including CAD), exercise testing is recommended as a
means of stratifying risk.243 Similarly, patients on antihyper-
tensive therapy may benefit from exercise testing before train-
ing as a means of adjusting their exercise prescription.
Cardiac arrest is more likely to occur during exercise than at
rest, and this association is much greater in sedentary than
active persons.244 Thus, when a sedentary person starts an
exercise program, there is presumably a period of increased
risk. For this reason, it has been recommended that middle-
aged or older (ie, older than 40 to 50 years) men should
undergo a screening exercise test if an exercise program more
vigorous than walking is to be pursued. However, in asymp-
tomatic patients without known cardiac disease, the absolute
risk of a major cardiac event during activity is still small,245 and
there are no data to justify or criticize testing. In the LRC study
of 3617 hypercholesterolemic men, the predictive value of a
positive exercise test result for subsequent activity-related
events was only 0.3% over 1 year and 4% over 7.4 years.246
SPECIAL GROUPS. Persons whose occupation may impact
public safety (airline pilots, truck or bus drivers, railroad
engineers, firefighters, and law enforcement officers) often
undergo periodic exercise testing for assessment of exercise
capacity and prognostic evaluation of possible coronary dis-
ease. There are insufficient data to justify this approach,
although in some cases, evaluations are done for statutory
reasons.
Implications for Clinical Practice. The use of exercise test-
ing for identification of CAD in asymptomatic persons is a
controversial topic for which the committee had difficulty
defining guidelines concordant with widespread current prac-
tice. The existing data indicate that although disease may be
identified, many more patients have false-positive test results.
The consequences of such findings include unnecessary and
expensive additional testing, adverse psychological implica-
tions, and misuse of data to influence employment and insur-
ance decisions. Before performing an exercise test on an
asymptomatic patient, these issues must be discussed and
informed consent obtained. In view of these limitations, a
minority of the committee favored a Class III recommendation
for the use of exercise testing as a screening technique for
CAD in patients with multiple risk factors or asymptomatic
men older than 40 years or women older than 50 years who
plan to start vigorous exercise.
The response to a positive exercise test should be modu-
lated by the remainder of the exercise data, including exercise
capacity, blood pressure response to exercise, and nonexercise
considerations such as risk factor status. The response to the
test might therefore vary from risk factor modification for a
positive result in the absence of other risk variables to further
investigation with an imaging protocol and treatment of CAD
in patients with a markedly positive test result and multiple risk
factors.
Valvular Heart Disease
Class I
1. None.
Class IIb
1. Evaluation of exercise capacity of patients with valvular
heart disease.*
Class III
1. Diagnosis of CAD in patients with valvular heart disease.
Rationale Uses of Exercise Testing in Patients With Valvular
Heart Disease. In symptomatic patients with documented val-
vular stenosis or regurgitation, the course of treatment is
usually clear and exercise testing is not required. However, the
development of Doppler echocardiography has increased the
number of asymptomatic patients with defined valvular abnor-
malities. The primary value of exercise testing in valvular heart
disease is to objectively assess atypical symptoms, exercise
capacity, and extent of disability, which may have implications
for medical, surgical, and social decision making. This is
*As noted earlier, the presence of symptomatic, severe aortic stenosis is a
contraindication to exercise testing.
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particularly of importance in the elderly, who are often asymp-
tomatic because they are inactive. The use of the exercise ECG
for diagnosis of CAD in these situations is limited by false-
positive responses due to LVH and baseline ECG changes.
Aortic Stenosis. Severe aortic stenosis is classically consid-
ered a contraindication to exercise testing, and this is unques-
tionable in patients with severe symptomatic aortic stenosis,
who should proceed to surgery. In truly asymptomatic patients,
aortic valve replacement is probably not justified on prognostic
grounds.247 However, many elderly patients in this situation
are asymptomatic because they are inactive, and planning
treatment on clinical grounds in these patients may be difficult.
The hemodynamic response to exercise may be of value in
selecting a subpopulation of asymptomatic patients who are
hemodynamically compromised by aortic stenosis, in whom
more aggressive therapy might be considered.
Exercise testing is an accepted means of evaluating pediat-
ric patients with aortic stenosis.248–250 Three studies in adults
with moderate to severe aortic stenosis (valve areas, 0.5 to
1.5 cm2; mean gradients, 18 to 64 mm Hg) have shown that
with the appropriate precautions, principally involving careful
observation of the patient with frequent blood pressure checks
during exercise, exercise testing can be safely performed in
patients with aortic stenosis.251–253 In these circumstances the
test should be directly supervised by a physician familiar with
the patient’s condition, and exercise should be terminated for
inappropriate blood pressure augmentation, slowing of the
heart rate with increasing exercise, or premature beats. If the
blood pressure response to exercise is abnormal, a cool-down
period on the treadmill is advisable to avoid left ventricular
volume overload provoked by assuming a supine position.
Functional limitation is commonly found in “asymptomat-
ic” patients with aortic stenosis.254 Apart from exercise capac-
ity, other important responses include a rapid augmentation of
heart rate (which implies a fixed stroke volume) and either
failure to augment systolic blood pressure with exercise or
decreasing pressure with increasing workload.
Mitral Stenosis. Patients with severe mitral stenosis have a
fixed stroke volume and are only able to augment cardiac
output by increasing heart rate. Because the major indication
for surgery in mitral stenosis is symptom status, exercise testing
is of most value when a patient is thought to be asymptomatic
due to inactivity or a discrepancy exists between the patient’s
symptom status and the valve area. When exercise testing is
performed to clarify these issues, excessive heart rate re-
sponses to a relatively low level of exercise, reduction of
cardiac output with exercise (evidenced by exercise-induced
hypotension), and chest pain (due to ischemia secondary to low
cardiac output, or pulmonary hypertension) are indicators in
favor of earlier surgery.
Aortic Regurgitation. Because volume overload is less de-
manding on the heart than pressure overload, and because the
reduction of diastolic duration with exercise favors forward
cardiac output, exercise capacity is maintained until late in the
course of aortic regurgitation. The decision to proceed to valve
surgery is based on symptom status, left ventricular systolic
dysfunction, and left ventricular size.255 Because ejection frac-
tion is a reliable index of left ventricular function in aortic
regurgitation, decisions regarding surgery are largely based on
resting ejection fraction, and exercise testing is not commonly
required, unless symptoms are ambiguous. The left ventricular
response to exercise may be used to follow the response of
asymptomatic patients to medical therapy.256
Mitral Regurgitation. Mild and moderate mitral regurgita-
tion are generally well compensated, although exercise testing
in these situations for assessment of CAD is often compro-
mised by false-positive ST-segment changes, particularly in
patients with mitral valve prolapse. Patients with severe mitral
regurgitation may demonstrate reduction of exercise capacity
and exercise-induced hypotension. As resting ejection fraction
is a poor guide to ventricular function in patients with mitral
regurgitation, combinations of exercise and assessment of left
ventricular function may be of value in documenting occult
dysfunction and provoking earlier surgery.257 Recently the
documentation of exercise-induced mitral regurgitation in
patients with mitral valve prolapse but without regurgitation at
rest has been associated with the subsequent development of
progressive mitral regurgitation, congestive heart failure, and
syncope.258
Exercise Testing Before and After Revascularization
Class I
1. Demonstration of ischemia before revascularization.
2. Evaluation of patients with recurrent symptoms suggesting
ischemia after revascularization.
Class IIa
1. After discharge for activity counseling and/or exercise train-
ing as part of cardiac rehabilitation in patients who have
undergone coronary revascularization.
Class IIb
1. Detection of restenosis in selected, high-risk asymptomatic
patients within the first months after angioplasty.
2. Periodic monitoring of selected, high-risk asymptomatic
patients for restenosis, graft occlusion, or disease progres-
sion.
Class III
1. Localization of ischemia for determining the site of inter-
vention.
2. Routine, periodic monitoring of asymptomatic patients
after percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass graft without specific
indications.
Rationale Exercise Testing Before Revascularization. Pa-
tients who undergo myocardial revascularization should have
documented ischemic or viable myocardium, especially if they
are asymptomatic.3,4,259 Frequently, however, this requires a
more sensitive test than the exercise ECG, particularly in the
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setting of one-vessel disease, especially if the revascularized
vessel supplies the posterior wall. Moreover, use of the exercise
ECG is inappropriate in situations in which the culprit vessel
must be defined. Documentation of baseline exercise capacity
may be worthwhile in patients undergoing either myocardial
revascularization or valvular interventions.
Exercise Testing After Revascularization. It is recognized
that there are two phases after revascularization. In the early
phase the goal of exercise testing is to determine the immedi-
ate result of revascularization. In the second or late phase the
goal of exercise testing is to assist in evaluation and treatment
of patients 6 months or more after revascularization, ie, with
chronic established CAD (as outlined in section III).
Exercise testing may be helpful in guiding an appropriate
cardiac rehabilitation program and return-to-work decisions.
(See section IV.)
Exercise Testing After Coronary Bypass Graft Surgery. In
symptomatic patients, exercise testing may be used to distin-
guish between cardiac and noncardiac causes of recurrent
chest pain, which is often atypical after surgery. Incomplete
revascularization or graft occlusion may be identified with the
exercise ECG,260 although not all results have been favor-
able.261 Because of concerns about the accuracy of the exercise
ECG in this group and because management decisions are
based on not only the presence but the site and extent of
ischemia, the exercise ECG is less desirable than stress-
imaging tests.262
In asymptomatic patients, there is concern about develop-
ment of silent graft disease, especially with venous conduits.
The conversion of a markedly positive test result done preop-
eratively to a negative postoperative test result does correlate
with successful revascularization.263 However, in a follow-up
study of events following exercise testing and evaluation of left
ventricular function, the left ventricular ejection fraction, but
not exercise variables, was predictive of outcome.264 This may
reflect lower sensitivity of the exercise ECG for ischemia and
may be less true using stress imaging tests.
The exercise ECG has a number of limitations after coro-
nary bypass surgery. Resting ECG abnormalities are frequent,
and if an imaging test is not incorporated in the study, more
reliance must be placed on symptom status, hemodynamic
response, and exercise capacity. Because of these consider-
ations, together with the need to document the site of isch-
emia, stress imaging tests are more favored in this group,
although there are insufficient data to justify recommending a
particular frequency of testing.
Exercise Testing After Percutaneous Transluminal Coronary
Angioplasty. Restenosis remains the single major limitation of
percutaneous coronary interventions. This clinical end point
reflects a complex underlying pathophysiology involving vari-
ous combinations of residual coronary stenosis, recoil, and
neointimal proliferation. Unfortunately, symptom status is an
unreliable index to development of restenosis; many patients
complain of noncardiac pain after angioplasty (false-positive
symptoms), and many persons experience silent ischemia
(false-negative symptoms). Silent restenosis is a common clin-
ical manifestation, with 25% of asymptomatic patients docu-
mented as having ischemia on exercise testing.265
Because residual plaque is responsible for a significant
proportion of restenosis, several centers have reported success
in performing exercise testing early (1 to 3 days) after PTCA.
The presence of ischemia in these tests is predictive of
restenosis.266 While ST-segment changes are a univariate
predictor, the independent predictor at multivariate analysis
proved to be ischemia on myocardial perfusion imaging.
Moreover, in addition to the benefit of early exercise testing
for the prediction of subsequent restenosis, the use of an
exercise test within 1 to 3 days of angioplasty may facilitate
earlier return to work and daily living activities,267 although the
safety of this approach has not been established, and exercise
when unstable plaque exists may (at least theoretically) risk
vessel occlusion.
If the aim of exercise testing is to identify restenosis rather
than predict its probability of occurrence, patients may be
tested later (for example, 3 to 6 months) after PTCA. Table 25
summarizes the variability in predictive value of the exercise
test for restenosis,268–275 partly reflecting varying populations
studied, frequency, and criteria for restenosis. False-positive
study results may be due to incomplete revascularization and
angiographically unrecognized plaque fissures. False-negative
Table 25. Predictive Value of Exercise Electrocardiographic Testing for Identification of Restenosis After Percutaneous Transluminal
Coronary Angioplasty
Author (year) n Clinical Post-PTCA (m) Restenosis (%)
PV1
(%)
PV2
(%) Definition of Restenosis
Kadel268 (1989) 398 Consecutive Up to 6 33 66 75 . 70% luminal diameter stenosis
Honan269 (1989) 144 Post MI 6 40 57 64 .75% luminal diameter stenosis
Schroeder270 (1989) 111 Asymptomatic 6 12 53 63 . 70% luminal diameter stenosis
Laarman271 (1990) 141 Asymptomatic 1 to 6 12 15 87 . 50% luminal diameter stenosis
el-Tamimi272 (1990) 31 Consecutive 6 45 100 94 Loss of . 50% initial gain of
lumen diameter
Bengtson265 (1990) 200 Asymptomatic (n 5 127) 6 44 46 63 . 75% luminal diameter stenosis
200 Symptomatic (n 5 66) 6 59 76 47 . 75% luminal diameter stenosis
Roth273 (1994) 78 1-vessel CAD 6 28 37 77 . 50% luminal diameter stenosis
Desmet274 (1995) 191 Asymptomatic 6 33 52 70 . 50% luminal diameter stenosis
PTCA indicates percutaneous transluminal coronary angioplasty; PV, predictive value; MI, myocardial infarction; and CAD, coronary artery disease.
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results may be caused by the failure of moderate (angiographi-
cally but not functionally significant) one-vessel stenoses to
lead to significant ischemia. Some authorities have advocated
routine testing, because restenosis is frequent and commonly
induces silent ischemia. The rationale of this approach is that
ischemia, whether painful or silent, worsens prognosis.276,277
The alternative approach, which the committee favors, is to use
a selective evaluation in patients considered to be at particu-
larly high risk, because the prognostic benefit of controlling
silent ischemia needs to be proved. Examples of patients who
are likely to be at high risk include those with decreased left
ventricular function, multivessel CAD, proximal left anterior
descending disease, previous sudden death, diabetes mellitus,
hazardous occupations, and suboptimal PTCA results. Which-
ever policy is followed, the exercise ECG is an insensitive
predictor of restenosis, with sensitivities ranging from 40% to
55%, significantly less than those obtainable with SPECT5,278
or exercise echocardiography.6,279 The insensitivity of the
exercise ECG probably reflects the high prevalence of one-
vessel disease in this population.
In conclusion, the lower sensitivity of the exercise ECG
(compared with imaging techniques) as well as its inability to
localize disease limits its usefulness in patient management
both before and after intervention. Despite the large numbers
of procedures performed and widespread variation in use of
exercise testing in this context, there are insufficient data to
justify a particular testing regimen after intervention.
Investigation of Heart Rhythm Disorders
Class I
1. Identification of appropriate settings in patients with rate-
adaptive pacemakers.
Class IIa
1. Evaluation of patients with known or suspected exercise-
induced arrhythmias.
2. Evaluation of medical, surgical, or ablative therapy in
patients with exercise-induced arrhythmias (including atrial
fibrillation).
Class IIb
1. Investigation of isolated ventricular ectopic beats in middle-
aged patients without other evidence of CAD.
Class III
1. Investigation of isolated ectopic beats in young patients.
Evaluation of Patients With Known or Suspected Exercise-
Induced Arrhythmias Use of exercise testing in patients with
syncope may identify those with CAD, although this is not
usually the cause of syncope. Syncope due to sinus node
dysfunction, atrioventricular block, and tachycardias may also
be identified.
Ventricular Arrhythmias. Exertional syncope due to tachy-
cardias may reflect the presence of ischemia, other structural
abnormalities that induce an abnormal cardiac response to
stress, and increased circulating catecholamines. The useful-
ness of exercise testing in patients with VT is variable, accord-
ing to the cause of the tachycardia. In some syndromes, such as
right ventricular outflow tract tachycardia in a normal heart,
VT may be reproducibly induced during exercise testing. In
adrenergic-dependent rhythm disturbances (including mono-
morphic VT as well as polymorphic VT related to long QT
syndromes), ambulatory ECG monitoring may fail to supply
the circumstances necessary for induction of VT, particularly if
the patient is sedentary and the arrhythmia is infrequent. Use
of exercise testing is therefore a useful prelude to electrophys-
iological study. Moreover, exercise testing may be of prognos-
tic value in these patients: 12-month mortality is three times
greater in persons exhibiting exercise-induced ectopy than
those with ectopy at rest only,280 and in patients with exercise-
induced ectopy, mortality of those with complex ectopy ex-
ceeds that of those with simple ectopy.281 In patients on
antiarrhythmic therapy, sustained exercise-induced VT is as-
sociated with a high risk of sudden death,282 and exercise
testing has been used to unmask proarrhythmic responses.
While serious arrhythmias are uncommon in unselected
populations undergoing exercise testing,283 the use of maximal
exercise testing in patients at risk of ventricular arrhythmia is
associated with a 2.3% incidence of arrhythmias requiring
cardioversion, intravenous drugs, or resuscitation.284 Nonethe-
less, even in this population, testing can be performed with low
mortality and few lasting morbid events. The main limitation of
exercise testing in patients with malignant ventricular arrhyth-
mias is related to its limited reproducibility. While it is
sufficiently reproducible to serve as an adjunct in the evalua-
tion and treatment of these patients,285 other testing is also
required.
Supraventricular Arrhythmias. Patients developing su-
praventricular arrhythmias during exercise often display
marked tachycardia due to their heightened adrenergic state.
In patients with Wolff-Parkinson-White syndrome, exercise
testing may be used to help evaluate the risk of developing
rapid ventricular response during atrial arrhythmias. Abrupt
loss of preexcitation during exercise infers a longer antegrade
refractory period in the accessory pathway than the atrioven-
tricular node. It is unlikely that a rapid ventricular response
will occur at heart rates above this rate. However, this response
to exercise may be difficult to recognize because the adrenergic
state speeds conduction in the atrioventricular node and
therefore reduces the area of myocardium that is stimulated
prematurely from the accessory pathway.
In patients with atrial fibrillation, the ventricular response is
governed by the atrioventricular node, and the heart rate is
therefore dependent on the rate of repolarization and the
effective refractory period, both of which may be influenced by
antiarrhythmic drugs used for rate control in patients with
atrial fibrillation. Effective rate control at rest does not neces-
sarily signify adequate rate control during exercise, and the
titration of additional drugs for this purpose may be facilitated
by exercise testing. The heart rate response to exercise in atrial
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fibrillation comprises an initial reduction of heart rate, fol-
lowed by delayed acceleration in very early exercise and an
exaggerated heart rate response. Prolonged tachycardia often
persists into the recovery period. In patients on medication,
95% demonstrate an abnormal chronotropic response early
during exercise (74% being fast), and 84% demonstrate an
abnormal chronotropic response during late exercise (53%
being slow). Thus, the majority of patients with atrial fibrilla-
tion demonstrate an abnormal chronotropic response to exer-
cise.286
Sinus Node Dysfunction. Exercise testing may distinguish
resting bradycardia with a normal exercise heart rate response
(which is seen in well-trained subjects with predominant
parasympathetic tone) from sinus node dysfunction with rest-
ing bradycardia and in patients who fail to make an exercise
response. Chronotropic incompetence has been variously de-
fined, the most common definition being failure to achieve
85% of age-predicted maximum heart rate (ie, more than two
standard deviations below age-predicted maximum).287 The
use of a heart rate response less than 100 bpm with maximal
exercise288 is specific but insensitive. A more complicated
definition, recently shown to be prognostically significant,289 is
the ratio between heart rate and metabolic reserve used by
stage II of the Bruce protocol.290 Using various definitions,
some authors have reported chronotropic incompetence in
patients with sinus node dysfunction, whereas others have
identified the sensitivity and specificity of this marker for sinus
node dysfunction as being suboptimal. Moreover, exercise
testing has limited reproducibility in this respect, and a normal
test result does not negate the possibility of sinus node
dysfunction. The use of exercise testing may, however, be
particularly useful in showing the benefits of sensor-triggered
rate-adaptive pacing, both in terms of absolute heart rate
attained and the rate of increase of heart rate.
Cardiac Pacemakers The previous edition of the ACC/
AHA guidelines for exercise testing291 suggested that exercise
testing was inappropriate in most patients with a permanent
pacemaker. Indeed, this remains true from a diagnostic stand-
point, and even the combination of exercise testing with
imaging may be problematic for the diagnosis of coronary
disease. However, the development of adaptive rate pacing
using various physiological sensors has led to study of the
exercise response being an important constituent in fine-tuning
these devices.292,293 Additionally, a number of studies have
compared different pacing modes with respect to their influ-
ence on exercise capacity. In all of these situations, however, a
formal exercise test may not be necessary, and the required
data could be obtained during a 6-minute walk.294
Exercise testing in patients with implantable cardiac defi-
brillators (ICDs) may provoke arrhythmias or ICD discharge.
Before testing, the programmed detection interval of the
device should be known. If the device has been implanted for
ventricular fibrillation (VF) or fast VT, this rate will normally
exceed that attainable during sinus tachycardia, and the test
can be terminated as the heart rate approaches 10 bpm below
the detection interval of the device. Indeed, this approach is
informative if the test is being performed to assess the risk of
sinus rate crossover.295 In patients with slower programmed
detection rates, the ICD may be reprogrammed to a faster
rate for the test, or temporarily deactivated (usually by
superimposition of a magnet). Care should be taken to avoid
unnecessary shocks as they are both unpleasant and poten-
tially hazardous.296
VII. Pediatric Testing: Exercise Testing in
Children and Adolescents
Class I
1. Evaluation of exercise capacity in children or adolescents
with congenital heart disease, those who have had surgery
for congenital heart disease, and children who have ac-
quired valvular or myocardial disease.
2. Evaluation of the rare child with a description of anginal
chest pain.
3. Assessment of the response of an artificial pacing system to
exertion.
4. Evaluation of exercise-related symptoms in young athletes.
Class IIa
1. Evaluation of the adequacy of response to medical, surgical,
or radiofrequency ablation treatment for children with a
tachyarrhythmia that was found during exercise testing
before therapy.
2. As an adjunct in assessment of the severity of congenital or
acquired valvular lesions, especially aortic valve stenosis.
3. Evaluation of the rhythm during exercise in patients with
known or suspected exercise-induced arrhythmia.
Class IIb
1. As a component of the evaluation of children or adolescents
who have a family history of unexplained sudden death
related to exercise in young individuals.
2. Follow-up of cardiac abnormalities with possible late coro-
nary involvement such as Kawasaki disease and systemic
lupus erythematosus.
3. Assessment of ventricular rate response and development
of ventricular arrhythmia in children and adolescents with
congenital complete atrioventricular block.
4. Quantitation of the heart rate response to exercise in
children and adolescents treated with b-blocker therapy to
estimate the adequacy of b-blockade.
5. Measurement of response of shortening or prolongation of
the corrected QT interval to exercise as an adjunct in the
diagnosis of hereditary syndromes of prolongation of the
QT interval.
6. Evaluation of blood pressure response and/or arm-to-leg
gradient after repair of coarctation of the aorta.
7. Assessment of degree of desaturation with exercise in
patients with relatively well-balanced or palliated cyanotic
congenital cardiac defects.
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Class III
1. Screening before athletic participation by healthy children
and adolescents.
2. Routine use of exercise testing for evaluating the usual
nonanginal chest pain common in children and adolescents.
3. Evaluation of premature atrial and ventricular contractions
in otherwise healthy children and adolescents.
Differences Between Pediatric and Adult Testing
Ischemic heart disease is rare in a young population. This
results in a much lower risk of routine testing as well as
differences in indications, usefulness, and interpretation of
exercise laboratory data in the pediatric population. Exercise
testing of children and adolescents has a very low risk com-
pared with testing of adults.297 Complications of pediatric
exercise testing are extremely infrequent, even when testing is
done in populations of children with congenital cardiac defects
and arrhythmias.9,297–300 Applications of exercise testing in the
young are most often related to measurement of exercise
capacity, evaluation of known or possible abnormalities of
cardiac rhythm, and evaluation of symptoms elicited by exer-
tion. Exercise testing is rarely needed to look for occult
coronary obstructions in the pediatric population. Exercise
capacity is diminished in some children or adolescents with
heart disease, and measurement is often useful in evaluating
subjective limitations.
Exercise testing in children provides a number of technical
challenges. Equipment must be modified for use by small
children. Testing protocols may need to be normalized by size
and weight. Norms for age and size on protocols being used are
required for proper test interpretation.9,300 Developmental
factors as well as interpretation of data figure into the conduct
of the test. Young children are less cooperative than older
persons with maximum exercise testing. Experience at encour-
aging the reluctant youngster to maximal effort is needed for
interpretable tests. It is usually difficult to differentiate limita-
tions of exercise capacity from a lack of cooperation in
pediatric testing. Because of this difficulty, ventilatory mea-
surements are used in many pediatric exercise testing labora-
tories to measure respiratory exchange ratio and ventilatory
anaerobic threshold.9,301
Exercise Testing for Specific Pediatric and
Congenital Cardiac Problems (Table 26)
Exercise Testing of Children and Adolescents With Chest
Pain Chest pain is common in children and adolescents.302,303
History and physical examination are generally adequate to
confidently provide reassurance to patient and family. These
episodes of benign chest pain are usually described as a brief
stabbing or shooting pain that occurs with or without exercise.
Pleuritic pain is common. Typical anginal symptoms are very
uncommon. Routine use of exercise testing for evaluation of
chest pain in children and adolescents is not required. Exercise
testing is appropriate for evaluation of the uncommon child
with chest pain that is typical angina by description and
consistently related to exercise. Exercise-induced broncho-
spasm is a cause of chest pain in children that is identified by
pulmonary function measurement test protocols.304
Exercise Testing of Patients With Unoperated Left-to-Right
Shunts Results of exercise testing in young persons with a
left-to-right intracardiac shunt such as an atrial septal defect, a
ventricular septal defect, or patent ductus arteriosus will
generally be normal if the magnitude of the shunt is moderate
or small. These persons are ordinarily asymptomatic, and
exercise testing adds little to routine evaluation of these
defects. Most of those with large shunts will be treated
surgically before they reach an age at which exercise testing is
practical. Older persons with a large left-to-right shunt often
have a low exercise capacity. Exercise testing may help confirm
or document subjective exercise impairment in these persons.
Testing is not routinely required to make decisions about
operative intervention in these older patients but can be of
considerable value if the history of limitation is unclear.
Patients with substantial diastolic runoff from a large left-
to-right shunt distal to the aortic valve (such as a large patent
ductus arteriosus with low pulmonary vascular resistance) will
occasionally have resting ST-segment depression due to a
relative insufficiency of coronary perfusion during diastole.
Left-to-right shunts beyond the tricuspid valve characteristi-
cally result in left ventricular volume overload, and large
shunts result in LVH. ST-segment depression on the exercise
ECG can be seen in these circumstances but provides little
benefit in decisions about surgical intervention. False-positive
exercise ECG changes are seen in some patients with left-to-
right intracardiac shunts who are treated with digoxin.
Limited exercise capacity, arrhythmias, ST-segment changes
on the exercise ECG, and/or decrease in oxygen saturation can
be seen in exercise testing of patients with left-to-right shunt
lesions who have developed severe elevations of pulmonary
vascular resistance (Eisenmenger syndrome).305,306 Exercise
testing is potentially hazardous in this group of patients and
generally should not be performed. Exercise testing has been
used to evaluate response to specific therapies intended to
diminish pulmonary resistance and improve pulmonary blood
flow.
Exercise Testing in Patients With Postoperative Left-to-
Right Shunts The great majority of patients in this group do
very well, and long-term follow-up studies have shown good
exercise performance in this group of patients many years
later.307–309 Routine exercise testing of these patients is not
required. Indications for use of exercise testing in this popu-
lation include symptoms related to exercise, known or sus-
pected arrhythmias related to exercise, and subjective limita-
tions of exertional capability. Atrial arrhythmias may develop
years after repair of atrial defects in some patients and are
often identified by exercise testing.310 Exercise testing is of
value as a part of evaluation of some patients with ventricular
arrhythmias with a ventricular septal defect that was repaired
in childhood.311 Exercise testing is also of value in the group
with an operated left-to-right shunt in whom pulmonary vas-
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cular resistance was elevated before surgery to evaluate both
exercise capacity and propensity to arrhythmia. Exercise test-
ing is often needed as part of the evaluation of the athlete after
surgery for a left-to-right shunt lesion.243
Exercise Testing With Unoperated or Palliated Cyanotic
Congenital Cardiac Defects Many of these patients will have
an operation before an age at which exercise testing is practi-
cal. Some will present late or are not suitable for an operation
other than a palliative procedure. Exercise capacity will usually
be less than average, and oxygen saturation will decrease with
exercise.312–314 Chronotropic response to exercise is impaired
with a low peak heart rate. Improvement in exercise capacity
can be demonstrated after a shunt procedure. Although exer-
cise testing answers specific questions in this group of patients,
Table 26. Exercise Test Findings in Children With Cardiac Abnormalities
Lesion Expected or Common Findings Concerning Findings
Aortic stenosis None Ischemic ST changes
Inadequate SBP response
Exertional symptoms
Postoperative aortic stenosis ST changes may be seen without predicting Arrhythmia
residual gradient Low VO2
Inadequate SBP response
Aortic regurgitation Same as postoperative aortic stenosis Same as postoperative aortic stenosis
Pulmonary stenosis None expected ST change rarely found with very severe pulmonic stenosis
Treated pulmonary stenosis None expected None expected
Aortic coarctation, preoperative or postoperative Hypertension Ischemic ST changes
Arm-to-leg systolic blood pressure gradient Diminished exercise capacity
Severe hypertension
Atrial septal defect Normal None expected
Ventricular septal defect None expected Arrhythmia
Poor exercise capacity if large shunt Desaturation
Mitral regurgitation None expected Low exercise capacity
Ischemic ST changes
Mitral prolapse False-positive ST changes common Arrhythmia
ST changes with hyperventilation
Hypertension Normal rise in SBP with exertion, SBP Ischemic ST changes
levels above normal for work rate Arrhythmia
Low exercise capacity
Cyanotic heart disease, palliated Low chronotropic response Profound desaturation
Desaturation with exercise Ischemia
Low exercise capacity Neurological changes
Postoperative Decreased chronotropic response Arrhythmias
Tetralogy of Fallot Low physical capacity Drop in systolic blood pressure
Right bundle branch block Desaturation
Postoperative arterial switch operation Uncertain significance of suggestions of
ischemia
Limited long-term data
Postoperative Mustard operation Decreased chronotropic response Arrhythmia
Poor exercise capacity Desaturation
ST changes in right precordial leads
Postoperative Fontan Low physical working capacity Profound cyanosis
Desaturation Arrhythmia
Drop in blood pressure during exercise
Kawasaki disease None expected Angina
Abnormal wall motion
Ischemic ST changes
Perfusion abnormality (nuclear)
Cardiomyopathy Low exercise capacity Syncope, light-headedness
Low peak HR, low VO2 Ischemic ST changes
Postoperative cardiac transplant Slow rise in heart rate Ischemic ST changes
Normal working capacity Low working capacity
Slightly low peak HR, normal VO2
High postexercise HR
Cardiac pacemakers Wenkebach at upper rate limit Abnormal (over or under) sensing ventricular arrhythmias
Exertional syncope None Angina
Mental status change
Ischemic ST changes
*Modified from Washington et al.9 with permission. SBP indicates systolic blood pressure, and HR, heart rate.
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there is not often a specific need for exercise testing in the
planning of surgical intervention for these children.
Exercise Testing for Patients With Coarctation of the Aorta
Before school age, exercise capacity and cardiopulmonary
function are usually normal after coarctation repair.315 Systolic
blood pressure during exercise and the postexercise arm-to-leg
gradient potentially is of use to the clinician in the attempt to
define whether a residual or recoarctation is present.316 When
patients with operated coarctation are tested, a greater arm-
to-leg blood pressure gradient is found immediately after
exercise than is found at rest. This has been thought to reflect
residual obstruction317 and has been used to compare results of
different surgical approaches.318,319 Some have used the post-
exercise arm-to-leg gradient as an indication for repeat cathe-
terization. Some observers have found that resting data are
sufficient to select those who require further intervention.
Factors other than residual obstruction may contribute to the
postexercise arm-to-leg gradient.320,321 Residual gradients
during exercise may ultimately lead to hyperdynamic ven-
tricular function and resting upper extremity hypertension.322
Exercise-induced systolic blood pressure elevation has been
thought to indicate residual obstruction,323,324 but the wide
range of variability in blood pressure response of normal
children makes it difficult to use systolic blood pressure
response alone in assessment of severity of residual coarcta-
tion.316 Among pediatric cardiologists, there has been great
variability in the use of exercise blood pressure data in
planning further interventions in coarctation of the aorta.325
Exercise testing may play an important role in evaluation of
suitability for high-intensity sports participation after success-
ful treatment of coarctation of the aorta.243 Exercise testing is
occasionally useful with coarctation of the aorta in assessing
the hemodynamic significance of other associated cardiac
defects (such as aortic valve disease).
Exercise Testing for the Child or Adolescent With Pulmo-
nary Stenosis Although the transvalvular pressure gradient in
pulmonary stenosis increases with exercise,326,327 natural his-
tory data and strategies for intervention are based on resting
measurements. Ventricular arrhythmia, cyanosis (from right-
to-left shunting through a patent foramen ovale), or ischemic
ST-segment changes develop with exercise in persons with
severe pulmonary stenosis. Abnormalities in right ventricular
function identified with exercise improve following relief of the
obstruction.328 Exercise testing is not required for manage-
ment decisions in the majority of cases with pulmonary steno-
sis. Although exercise testing is not commonly needed for
decisions about advisability for participation in high physical
intensity sports after treatment of pulmonary stenosis,243 ath-
letes with severe pulmonary valve incompetence and a dilated
right ventricle may require assessment before participation in
sports.
Exercise Testing for the Child or Adolescent With Aortic
Stenosis or Regurgitation Exercise testing has been used to
help assess the severity of obstruction in children with aortic
stenosis.248–250 Before the development of reliable echocardio-
graphic and Doppler methods, there was a greater need to rely
on exercise testing for children with aortic stenosis for assess-
ment of the severity of aortic obstruction. Abnormalities found
on exercise testing of children with aortic stenosis include
ST-segment changes with exercise,250,329 a drop in blood
pressure or failure of appropriate increase in blood pressure
with exercise,330 and development of arrhythmias during exer-
cise testing.331 Although exercise-induced ST-segment changes
have been correlated with the severity of obstruction, the
resting gradient is not the sole determinant of these ST-
segment changes. The major hemodynamic determinant of ST
depression during exercise in patients with aortic stenosis
seems to be the left ventricular oxygen demand supply ratio.329
ST depression with exercise testing improves when the gradi-
ent has been relieved surgically,331 although abnormalities
after treatment seem to be of less predictive value than in
unoperated patients.332 Blood pressure response to exercise is
extremely variable in children without heart disease, and lack
of a rise in blood pressure with exercise is often seen in normal
children. Although blood pressure rises less in children with
severe aortic stenosis than it does in control subjects, blood
pressure response is not diagnostic in individual patients.
Critical aortic stenosis can be identified by findings on
examination and confirmed by echocardiography. Although
the exercise test is likely to be abnormal in this setting, testing
carries some risk, and the decision to recommend intervention
is made without requiring exercise testing. Another group of
patients who have very mild aortic stenosis can also be
confidently identified by expert examination, confirmed, if
necessary, by echocardiography. The exercise test adds little to
assessment of severity in this group of patients, and an
abnormal test result is likely to be a false-positive result.
Exercise testing can provide useful information in combination
with other data for management decisions about patients with
aortic stenosis that is neither obviously quite severe or very
mild. There are no criteria for operative intervention based on
results of exercise testing alone.
Exercise testing is often used for issues of the advisability of
sports participation by children with aortic stenosis and for
children who have had treatment of aortic stenosis.243
Aortic regurgitation causes left ventricular dilation with
static or dynamic exercise, and ST-segment changes during
exercise are expected with hemodynamically significant aortic
regurgitation. ST-segment changes in children with aortic
stenosis and regurgitation are inaccurate in predicting gradi-
ent.333 Exercise testing is often useful in evaluation of exercise
capacity of children with aortic regurgitation and evaluation
before participation in sports.243
Exercise Testing After Surgery for Tetralogy of Fallot
Exercise capacity improves after successful repair of tetralogy
of Fallot. Low exercise capacity is found in many persons with
significant residual hemodynamic abnormalities. Exercise test-
ing has been used to identify children with arrhythmias.
Complex ventricular arrhythmias observed during exercise
testing are correlated with a risk of sudden cardiac death.
Serial testing has been used to demonstrate the effectiveness of
an antiarrhythmic therapeutic regimen. The possibility of late
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development of arrhythmia after repair of tetralogy of Fallot
led to a recommendation for periodic exercise testing (every 3
or 4 years) in postoperative tetralogy patients. This recommen-
dation is most applicable to older patients who underwent
surgery sometime ago. Diastolic restrictive physiology with
exercise has recently been shown to predict a better long-term
functional situation for patients with tetralogy of Fallot.334
Exercise testing is often needed as part of the evaluation
before intense athletic training and competition for these
patients, primarily to assess their propensity to arrhythmias.
Exercise Testing After the Fontan Operation (Total Sys-
temic Venous to Pulmonary Connection) Low exercise capac-
ity, low cardiac output and low oxygen uptake, development of
atrial or ventricular arrhythmias with exercise, limitation of
peak exercise heart rate response, and development of cyano-
sis is usual with exercise testing in this group of patients.
Improvement in exercise capacity compared with preoperative
status can be demonstrated.314,335,336 Exercise testing is helpful
in evaluation of exercise capacity and screening for arrhythmia
in the postoperative Fontan patient.
Exercise Testing of Patients With Cardiomyopathy Exer-
cise testing of children with hypertrophic cardiomyopathy has
not been a routine part of evaluation. Children with severe
hypertrophy or obstruction are at risk for complications with
exercise. Arrhythmias, ST-segment changes, drop in blood
pressure, and low exercise cardiac output occur with test-
ing.337,338 Exercise testing is sometimes useful to help evaluate
response to a specific therapy in patients with hypertrophic
cardiomyopathy.
Children with dilated cardiomyopathy are likely to have a
limited exercise capacity. ST-segment changes are often seen.
The exercise test can be of value in identifying arrhythmias.
Survival correlates with impaired exercise capacity. Informa-
tion about exercise limitation influences decisions about the
timing of cardiac transplantation.
Restrictive cardiomyopathy is less common than dilated or
hypertrophic cardiomyopathy. These children tend to be iden-
tified later and seem less ill than those with dilated cardiomy-
opathy, although the time interval from diagnosis to death is
shorter.339 Near-normal exercise capacity is falsely reassuring
in this setting.
Exercise Testing of Children or Adolescents With Syncope
Features of syncope that suggest a potentially life-threatening
cardiac event include an abrupt loss of consciousness (as
opposed to a prodrome or aura), injury on impact (as opposed
to a gradual “slump”), and syncope related to physical activity.
Evaluation for possible arrhythmia, left ventricular outflow
obstruction, and cardiomyopathy is appropriate. Exercise test-
ing is an important component of evaluation of children or
adolescents who have unexplained syncope related to physical
exertion.
Exercise Testing of Children or Adolescents With Atrial
Arrhythmias Premature atrial contractions are common and
benign in young persons. Exercise test evaluation of premature
atrial contractions in pediatric patients is not required.
The majority of children with supraventricular tachycardia
will not have exercise-induced tachycardia. Exercise testing
helps in evaluation of selected cases in which the history
suggests an exercise-related tachycardia. Serial exercise testing
has been used to follow the response to therapy in cases of
exercise-induced atrial tachycardias.
Exercise Testing of Children or Adolescents With Ventric-
ular Arrhythmias Isolated premature ventricular depolariza-
tions in asymptomatic children and adolescents usually disap-
pear with the higher heart rates associated with exercise. It is
not necessary to perform formal laboratory testing to demon-
strate this.
Exercise testing is often of value in diagnosing VT and
assessing the efficacy of treatment. VT with exercise is often
observed in children with no structural heart abnormality as
well as in children with myocarditis, cardiomyopathy, or a
congenital cardiac malformation. Arrhythmogenic right ven-
tricular dysplasia is particularly related to development of VT
with exercise.
Measurement of the response of the shortening or prolon-
gation of the corrected QT interval to exercise has been used
as an adjunct in the diagnosis of hereditary syndromes of
prolongation of the QT interval. Accuracy of measurement is
suspect, and its usefulness for decision making in borderline
cases has been questioned. T-wave alternans is a relatively
specific but uncommon finding with exercise testing in patients
with long QT-interval syndromes. Exercise testing occasionally
identifies VT.
Exercise Testing of Children or Adolescents With Conduc-
tion Abnormalities and in Pacemaker Follow-up Ventricular
rate response to exercise and development of ventricular
arrhythmia with congenital complete atrioventricular block is
useful in determining the need for artificial pacing. Assessment
of sensing and capture of an artificial pacing system during
exercise is useful in some cases. Exercise testing to evaluate the
adequacy of rate responsiveness to exercise is useful in man-
agement.
Exercise Testing of Children or Adolescents With Known
or Suspected Coronary Artery Disease Some cardiac abnor-
malities in childhood are predicted to be associated with
development of coronary artery involvement later in life.
Examples include persons who had surgery for anomalous left
coronary artery from the pulmonary trunk (Bland-Garland-
White syndrome). Some cases of tetralogy of Fallot include an
anomalous right coronary artery arising from the left coronary
artery or from the left sinus of Valsalva and crossing the right
ventricular outflow tract in proximity to the infundibular
resection. One concern has been possible coronary anasto-
motic obstruction late after neonatal arterial switch operation
for transposition of the great arteries in which the coronary
ostia must be translocated. Kawasaki disease with coronary
aneurysms in early life is another possible source of develop-
ment of coronary artery insufficiency. Exercise testing of
asymptomatic youths in these categories before intense athletic
competition and testing if symptoms of possible ischemic origin
develop is indicated.
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Exercise Testing of Children or Adolescents With Cardiac
Transplantation Exercise for the patient with a transplanted
heart is characterized by a relative inertia of the chronotropic
response. Because of cardiac denervation, the heart rate rises
in response to circulating catecholamines more slowly than in
normal children. Exercise capacity is in the normal range in
most patients. Some degree of reinnervation sometimes occurs
years after transplantation, but anginal pain is often absent
with transplant CAD. Bundle branch block is a common
finding that limits the usefulness of exercise electrocardiogra-
phy in this population. Exercise testing for ischemic changes
has not supplanted periodic surveillance coronary angiography
at pediatric transplant centers but is a useful adjunct in
following children with heart transplants. The sensitivity and
specificity of exercise testing for evaluation of posttransplant
CAD in children is unknown.
Exercise Testing After an Operation to Correct Transposi-
tion of the Great Arteries The arterial switch operation is the
current surgical treatment of transposition of the great arteries
in most cases. Normal exercise tolerance and normal ST
segments with exercise are seen in this group of children,
although the length of follow-up available is less than for many
other operations. Perfusion defects seen by radionuclide exer-
cise testing are of uncertain significance.
Many older persons with transposition underwent repair
with an atrial baffle. Exercise capacity and heart rate response
to exercise are likely to be limited in this group of patients,
although many are doing very well.340 An inadequate chrono-
tropic response is related to development of right ventricular
dilation341 and ultimately the need for a pacemaker.342
Appendixes
Appendix 1
Borg Scale for Rating Perceived Exertion Table A1 shows
the original scale for rating perceived exertion (6 to 20) (left)
and the newer 10-point category scale with ratio properties
(right).
Appendix 2
Multivariable Analysis for the Diagnosis of Obstructive
Coronary Artery Disease The following examples of multiva-
riable equations that can estimate the presence of angio-
graphic CAD were chosen because they have been validated in
large populations.
Morise et al343 studied a total of 915 consecutive patients
without a history of prior myocardial infarction or coronary
artery bypass surgery who were referred to the exercise labo-
ratory at West Virginia University Medical Center between
June 1981 and December 1994 for evaluation of coronary
disease. All patients had coronary angiography within 3
months of the exercise test. The patients were classified as
having disease if there was at least a 50% lumen diameter
narrowing in one or more vessels. When this criterion was
used, the prevalence of disease in this population was 41%.
Morise generated the following logistic regression equation:
Probability (0-1)51/(1 1 e 2 (a 1 bx 1 cy))
where a is the intercept, b and c are beta coefficients, and x and
y are variable values as follows:
2.12 1 (4.5* [23.61 1 (0.076* age) 2 (1.33* gender) 1 (0.64*
symptoms) 1 (0.65* diabetes) 1 (0.28* smoking) 2 (1.46* body
surface area) 1 (0.50* estrogen) 1 (0.33* number of risk factors)
2 (.40* resting ECG)]) 1 (0.37* mm ST depression) 1 (1.02* ST
slope) 2 (0.37* negative ST) 2(0.02* maximal heart rate)
Gender was coded as 1 for female and 0 for male. Symptoms
were classified into four categories: typical, atypical, nonangi-
nal pain, and no pain and coded with values of 4, 3, 2, and 1,
respectively. Diabetes was coded as 1 if present and 0 if absent.
Smoking was coded as 2 for current smoking, 1 for any prior
smoking, and 0 for never smoked. Estrogen was coded as 0 for
males, 1 for estrogen negative (postmenopausal and no estro-
gen), and 21 for estrogen positive (premenopausal or taking
estrogen). Risk factors included history of hypertension, hy-
percholesterolemia, and obesity (BMI $ 27 kg/m2 ). Resting
ECG was coded as 0 if normal and 1 if there were QRS or ST-T
wave abnormalities. Millimeters ST depression was coded as 0 for
women. ST slope was coded as 1 for downsloping and 0 for
upsloping or horizontal. Negative ST was coded as 1 if ST
depression was less than 1 mm depression horizontal or
downsloping or ST depression was less than 1.5 mm upsloping.
Detrano et al23 included 3549 patients from eight institu-
tions in the United States and Europe who underwent exercise
testing and angiography between 1978 and 1989. Disease was
defined as greater than 50% diameter narrowing in at least one
major coronary arterial branch, and the prevalence of disease
according to this criterion was 64%. They considered a total of
Table A1*
15-Grade Scale 10-Grade Scale
6 0 Nothing
7 Very, very light 0.5 Very, very weak (just noticeable)
8 1 Very weak
9 Very light 2 Weak (light)
10 3 Moderate
11 Fairly light 4 Somewhat strong
12 5 Strong (heavy)
13 Somewhat hard 6
14 7 Very strong
15 Hard 8
16 9
17 Very hard 10 Very, very strong (almost maximum)
18
19 Very, very hard Maximum
20
*From Borg GA. Med Sci Sports Exerc. 1982;14:377–381. Reproduced with
permission.
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15 clinical and exercise variables that contributed significant
and independent information to disease probability and had
been judged clinically relevant by a panel of cardiologists as
candidates for logistic regression. The selected Detrano equa-
tion intercept, variables, and coefficients are listed below:
1.9 1 (0.025* age) 2 (0.6* gender) 2 (0.11* symptoms) 2
(0.05* METs) 2 (0.02* maximal heart rate ) 1 (0.36* exercise-
induced angina ) 1 (0.59* mm ST depression)
Gender was coded as 1 for female and 21 for male. Symptoms
were classified into four categories: typical, atypical, nonangi-
nal pain, and no pain, and coded with values of 1, 2, 3, and 4,
respectively. Exercise angina was coded as 1 for presence and
21 for absence.
Appendix 3
Table A2 shows the results of 24 studies that used multivari-
able techniques to predict disease presence (30 equations were
created). The denominator is the number of equations that
allowed the particular variable to be a candidate for the equation.
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A
Abnormal test, positive predictive value of, 269
ACC Staff, 303
ACC/AHA
classifications, 264
Guidelines for Exercise Testing, 260
ACC/AHA Task Force on Practice Guidelines, 263
Accuracy of exercise testing, in asymptomatic
persons, 290
ACIP. See Asymptomatic Cardiac Ischemia Pilot
study
Activity counseling, exercise testing for, after
myocardial infarction, 284–285
Age. See also Elderly
pretest probability of coronary artery disease by,
266, 268t
Agency for Health Care Policy and Research, 279
AHA. See also ACC/AHA guidelines
Staff, 303
American Academy of Family Physicians, 264
American College of Cardiology. See ACC
American College of Physicians, 264
American College of Sports Medicine, 263, 264
American Heart Association. See AHA
American Society of Echocardiography, 263
American Society of Nuclear Cardiology, 263
Anaerobic threshold. See Ventilatory/anaerobic
threshold
Angina pectoris. See also Chest pain
atypical or probable, 268
end point, 290–291
during exercise, degree of, 278
stable, 279
typical or definite, 268
unstable, 275, 280
short-term risk of death or nonfatal infarction
in patients with, 279t, 279–280
vasospastic, 266
Angiography, 267f, 268
costs and availability of, 266, 266t
risks, in elderly, 287
Angioplasty, 280
percutaneous transluminal coronary, exercise
testing after, 295t, 295–296
postdischarge mortality related to, 282
Angiotensin-converting enzyme inhibitors, 280
Antihypertensive agents, influence on test
performance, 272
Aortic coarctation, exercise testing in pediatric
patients with, 299t, 300
Aortic regurgitation, exercise testing in, 294
in pediatric patients with, 299t, 300
Aortic stenosis, exercise testing in, 293
in pediatric patients with, 299t
Aortic valve, 298
Arrhythmias. See also specific type of arrhythmia
exercise-induced, known or suspected, evaluation
of patients with, 296–298
provoking of, 297
Arterial switch operation, postoperative exercise
testing in pediatric patients, 299t
Aspirin, 280
Asymptomatic Cardiac Ischemia Pilot (ACIP)
study, 290
Asymptomatic persons without known coronary
artery disease, exercise testing in, 290–293
Atherosclerosis, 279
aggressiveness of, 275
coronary tree, 275
early changes of, 290
Atrial arrhythmias, exercise testing in pediatric
patients with, 301
Atrial fibrillation, heart rate response to exercise
in, 296
Atrial septal defect, exercise testing in pediatric
patients with, 299t
Availability of exercise test, 265, 266
B
Bayes theorem, 269
Believability criteria for diagnostic tests, 270
b-Adrenergic blocking agents, 265, 280
influence on test performance, 272
after myocardial infarction, exercise test
response and, 283, 284
in pediatric patients, estimation of adequacy of,
297
Bias, work-up, avoiding of, 271
Bicycle exercise test, 263, 282. See also Cycle
egonometer
in elderly, 289
Bland-Garland-White syndrome, 301
Blood pressure. See also Hypertension
abnormal response to exercise testing, 294
monitoring of, 263, 264
after myocardial infarction, prognostic
implications, 283
systolic, 291
Borg scale
for rating of perceived exertion, 302, 302t
use of, 265
Bruce protocol, 277
modified, 282
standard, 282
Bundle branch block
left, 276, 283
electrocardiographic abnormalities associated
with, 272
right
electrocardiographic abnormalities associated
with, 272
C
CAMI study. See Canadian Assessment of
Myocardial Infarction study
Canadian Assessment of Myocardial Infarction
(CAMI) study, 280
Candidates for exercise testing, 266
Carbon dioxide (CO2)
analysis, 286
in expired air, 287
output (Vco2), 286
peak, 286
Cardiac arrest, during exercise testing, 293
Cardiac death
exercise-testing-related, after myocardial infarc-
tion, 283
prediction of, exercise testing for, 278, 279t,
279–280
Cardiac events, 274
prediction of, in asymptomatic patients, 292t
Cardiac function, parameters of, 286
Cardiac rehabilitation, after myocardial infarction,
exercise testing in, 285
Cardiomyopathy. See also Hypertrophy
exercise testing in, in pediatric patients with,
299t, 301
Cardioverter-defibrillator, implantable, discharge,
297
Chest pain, 264. See also Angina pectoris
causes of, 268
exercise testing in, 267f
in infants and children with, 297
ischemic, 265
Chronic coronary artery disease, 263
Chronotropic incompetence, in sinus node
dysfunction, 296
Chronotropic response to exercise
in elderly, 290
in supraventricular arrhythmias, 296
Class I conditions, exercise testing in
in asymptomatic patients without known
coronary artery disease, 290
in diagnosis of obstructive coronary artery
disease, 266
indications for, 264
for investigation of heart rhythm disorders, 296
after myocardial infarction in, 280
in pediatric patients, 297
before and after revascularization, 294
for risk assessment and prognosis in patients
with symptoms or prior history of coronary
artery disease, 274
using ventilatory gas analysis, 285
Class II conditions, exercise testing in
indications for, 264
after myocardial infarction in, 280
Class IIa conditions, exercise testing in
in diagnosis of obstructive coronary artery
disease, 266
indications for, 264
for investigation of heart rhythm disorders, 296
after myocardial infarction, 280
in pediatric patients, 297
before and after revascularization, 294
using ventilatory gas analysis, 285
Class IIb conditions, exercise testing in
in asymptomatic patients without known
coronary artery disease, 290
in diagnosis of obstructive coronary artery
disease, 266
indications for, 264
for investigation of heart rhythm disorders, 296
after myocardial infarction in, 280
in pediatric patients, 297
before and after revascularization, 294
for risk assessment and prognosis in patients
with symptoms or prior history of coronary
artery disease, 274
using ventilatory gas analysis, 285
for valvular heart disease, 293
Class III conditions, exercise testing in
in asymptomatic patients without known
coronary artery disease, 290, 293
for diagnosis of obstructive coronary artery
disease, 266, 268
indications for, 264
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for investigation of heart rhythm disorders, 296
in pediatric patients, 297
before and after revascularization, 294
for risk assessment and prognosis in patients
with symptoms or prior history of coronary
artery disease, 274
using ventilatory gas analysis, 286
for valvular heart disease, 293
Clinical practice, exercise testing in asymptomatic
patients and, 293
Computer processing, of exercise ECG, 274
Conduction abnormalities, exercise testing in, of
pediatric patients with, 301
Conflict of interest, 263
Congenital heart defects. See also specific defect
exercise testing for, 298–302
Contraindications to exercise testing, 264, 265t,
267f
Cool-down period, 294
Coordination, problems of in elderly, 289
Coronary artery bypass surgery. See Surgery,
coronary artery bypass
Coronary artery disease
chronic, 263
diagnosis of, 266
early, 290
in elderly, 289–290
exercise testing in
of pediatric patients with known or suspected,
301
for screening, 290
nonacute, symptomatic patients with, risk
assessment of, 276
obstructive. See Obstructive coronary artery
disease
prognosis of, general considerations, 274–275
risk assessment and prognosis in patients with
symptoms or prior history of, 274–280. See
also Risk assessment
three-vessel, 282
Coronary Artery Surgery Registry, 276
Coronary tree, atherosclerotic involvement of, 275
Cost
of exercise test, 265–266
of gas exchange measurement, 287
Cost-effectiveness of exercise testing, factors in, 263
Cox regression analysis, 277
Cut point, for obstructive coronary artery disease
diagnosis, 268, 269
Cyanosis, 300
congenital, exercise testing in patients with, 298,
299, 299t
Cycle ergometer, 264, 265
protocols, after myocardial infarction, 282
D
Death, cardiovascular
negative test results and, 291
probability of, 274
Defibrillators, implantable, exercise testing in
patients with, 297
Depolarization, premature ventricular, 301
Diabetes, 275, 291
multivariate analysis for diagnosis of obstructive
coronary artery disease and, 302
Diagnostic accuracy of standard exercise test, 270–
272
Diastolic pathology, in tetralogy of Fallot, 300
Diastolic runoff, 298
Digoxin, 282
influence on test performance, 272, 273
patients receiving, studies including, 271, 272
Dilation, left ventricular, 300
Discriminant value, for obstructive coronary artery
disease diagnosis, 268, 269
Disease prevalence, of obstructive coronary artery
disease, effect on predictive value of
positive test, 269, 269t
Doppler echocardiography, 293
Drugs, influence on test performance, 272
Duke Cardiovascular Disease Databank, 276
Duke treadmill score, 277, 278f
E
Echocardiography
of aortic stenosis, 300
stress, costs and availability of, 266, 266t
Ectopy, exercise-induced, 296
Egonometer. See Cycle egonometer
Eisenmenger syndrome, 298
Ejection fraction, 275, 295
Elderly
diagnosis of coronary artery disease in, 289–290
exercise testing in
sensitivity of, 269
for valvular heart disease, 293
Electrocardiography (ECG), 264
abnormalities, 272–273
after myocardial infarction, exercise testing
for, 280
exercise, 263
after coronary artery bypass, limitations, 295
diagnostic accuracy of, 270
diagnostic value of, 271
after myocardial infarction, meta-analysis of,
282, 283t
in women, accuracy of, 287–288
resting
abnormal, after myocardial infarction,
exclusion from exercise testing, 281–282
abnormalities, in elderly, 289
inability of interpretation, 267f
End points
in angina, 290–291
exercise, 265, 265t
non-ECG, in women, 288
Equipment, for exercise testing, 264, 265
Estrogen, multivariate analysis for diagnosis of
obstructive coronary artery disease and, 302
Exclusions from exercise testing, after myocardial
infarction, 281–282
Exercise, inability in, after myocardial infarction,
risk and prognosis related to, 282
Exercise capacity, 265
in asymptomatic patients without known
coronary artery disease, 291
markers of, 276, 276t
maximum, 276
left ventricular function and, 276
after myocardial infarction, prognostic
implications, 283
Exercise testing, 263
contraindications to, 264, 265t, 267f
persons performing, 264
procedure
clinical context, 266
cost and availability, 265–266
equipment and protocols, 264, 265
exercise end points, 265, 265t
general overview, 264
indications and safety, 264, 265t
interpretation of exercise test, 265
termination of, indications for, 265, 265t
Exercise testing modality, initial in symptomatic
patients with nonacute coronary artery
disease, 276
Exercise training. See Cardiac rehabilitation
Exertion, perceived, Borg scale for, 302. 302t
F
False-negative results, in exercise testing for resten-
osis, 295
False-positive results, 271, 291
in elderly, 289
in ST-segment evaluation, 288
Fatigue, assess of, 265
FEO2, 286
Fitness program, exercise testing of asymptomatic
patients before, 293
Flecainide, 272
Fontan procedure, exercise testing after, in
pediatric patients, 299t, 300
Foramen ovale, patent, 300
Functional capacity, assessment of, 265
G
Gait, problems of, in elderly, 289
Gas
expiratory, measurement of, during exercise
testing, 287
ventilatory. See Ventilatory gas measurement
Gas analyzers, rapid, 286
Gender. See also Males; Women
multivariate analysis for diagnosis of obstructive
coronary artery disease and, 302
pretest probability of coronary artery disease by,
266, 268t
GISSI-2 trial, 283
Global Utilization of Streptokinase and TPA for
Occluded Arteries (GUSTO) trial, 282
Graft disease, silent, 295
GUSTO trial. See Global Utilization of
Streptokinase and TPA for Occluded
Arteries trial
H
Handrail support, 286
Heart failure, exercise capacity in patients with,
287, 288t
Heart rate
adjustment, 273–274
excessive, 265
impairments, 265
maximum
after myocardial infarction, 282
regression line for, 265
monitoring of, 264
ST segment and, in women, 287, 288
target, 265
Heart rhythm disorders. See also Arrhythmias
investigation of, 296–297
Heart transplantation
candidates for, identification of, 263
exercise testing after, in pediatric patients, 299t,
301
High-risk exercise test results, patients with, 280
High-risk population, identification of, 276
History, pretest probability of obstructive coronary
artery disease based on, 268
Hypercholesterolemia, 275, 291
Hypertension, 275, 291
exercise testing in pediatric patients with, 299t
Hypertrophy. See also Cardiomyopathy
Hypertrophy, left ventricular, 266, 273, 282, 298
electrocardiographic abnormalities associated
with, 272
studies excluding, 272, 272t
studies including, 271, 271t
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Hyperventilation, 272
preexercise, 271
Hypotensive response to exercise, in elderly, 290
I
Imaging, 263
for symptomatic patients with nonacute coronary
artery disease, 276
Indications for exercise testing, 264, 265t
Inotropic response to exercise, in elderly, 290
Interpretation of exercise test, 265
Ischemia, 295. See also Myocardial ischemia
diagnosis of, 290
exercise- or stress-induced, 276
after myocardial infarction, 282, 283
localization of, 273
in pediatric patients, 297
K
Kawasaki disease, exercise testing in pediatric
patients with, 299t, 301
L
Lead, selection, 273
Left coronary artery, anomalous, 301
Left ventricular dysfunction
extent of, 274, 275
Left ventricular function, 274, 275t
in aortic regurgitation, 294
maximum exercise capacity and, 276
“Limited challenge,” 270
Lipid Research Clinics (LRC) studies, 290
Low-risk exercise test results, patients with, 280
M
Males. See also Gender
symptomatic, exercise testing in obtaining
prognostic information from, 291
Management strategy, election of, 274
Measurement values of test, overlap of, 268
Medicare fees and volumes for exercise test, 265–
266
MET level, peak, 282
Meta-analysis of exercise testing
in obstructive coronary artery disease diagnosis,
270t, 270–271, 272t
sensitivity of test from, 271
specificity of exercise from, 271
Metabolic equivalents (METS), of exercise, 265
Minute ventilation (VE), 286
increase in, 286
linearity of, departure of, 286
lowest value, 287, 288f
Mitral regurgitation
exercise testing in, 294
in pediatric patients with, 299t
exercise-induced, 294
Mitral stenosis, exercise testing in, 294
Mitral valve prolapse, 294
exercise testing in, in pediatric patients with,
299t
Mortality. See also Death, cardiovascular
exercise testing-induced, 264
Mortality rates, 277
after myocardial infarction, postdischarge, 282
MRFIT. See Multiple Risk Factor Intervention
Trial
Multiple Risk Factor Intervention Trial (MRFIT),
290, 291
Mustard operation, exercise testing in pediatric
patients after, 299t
Myocardial infarction, 273, 275
exercise testing after, 266, 280–281, 285
activity counseling, 284–285
for cardiac rehabilitation, 285
exercise test logistics, 281–282
risk stratification and prognosis, 282–284
safety in, 282
for therapies and treatment strategies, 280
exercise testing-induced, 264
fatal, 282
inferior, 281
nonfatal, 282
non-Q-wave, 279, 280, 283
prediction of, exercise testing for, 278, 279t,
279–280
prediction of disease severity after, 270
previous, exercise testing for obstructive
coronary artery disease in, 267f
Q-wave, 273, 281, 283
risk assessment after, 263
Myocardial ischemia, 268, 272
Myocardial perfusion imaging, 278, 295
Myocardial revascularization. See Revascularization
N
National Health Interview Survey, 289
Naughton protocol, modified, 282
Negative test results, subsequent cardiovascular
death and, 291
NHLBI, 290
Nitrates, 272
Nodal points, 266
O
Obstructive coronary artery disease
diagnosis of, multivariate analysis for, 302, 302t
exercise testing in diagnosis of, 266, 267f, 268
believability criteria for diagnostic tests, 270
diagnostic accuracy of standard exercise test,
270–272
diagnostic characteristics and test
performance, 268–270
electrocardiographic abnormalities, 272–273
factors influencing test performance, 272
overview of confounders: digoxin, resting ST
depression, left ventricular hypertrophy,
273
pretest probability, 268, 268t
rationale, 268
ST-segment interpretation issues, 273–274
Occupation, exercise testing and, 293
Oxygen (O2)
analysis, 286
consumption, 286
measurement, usefulness of, 263
peak, measurement of, 287, 288
in expired air (FEO2), 286, 287
uptake (VO2), 286
increase in, 286
lowest value, 287, 288f
maximal (VO2 max), 276, 286, 287
P
Pacemaker, exercise testing in patients with, 297
in pediatric patients, 299t
for follow-up, 301
Pediatric patients
exercise testing in, 297
in aortic stenosis, 293–294
differences between pediatric and adult
testing, 297–298
for specific pediatric and congenital cardiac
problems, 298–302
normal values for VAT in, 287
Perceived exertion scales, 265
Perfusion imaging. See Myocardial perfusion
imaging
Pharmacological stress study, 263, 276
for obstructive coronary artery disease, 267f
Plaque
coronary event, 275t
residual, after PTCA, 295t, 295–296
ruptured, 279
Population effect, for obstructive coronary artery
disease diagnosis, 269
Population screening, in asymptomatic patients
without known coronary artery disease, 291
Positive exercise test, 291
for obstructive coronary artery disease, effect of
disease prevalence on, 269, 269t
response to, 293
Positive predictive value, of abnormal test, 269
Posttest probability, of coronary artery disease, 290
Predischarge, exercise test in, 279, 280
after myocardial infarction, 282
clinical indications of high risk patients, 281f
Preexcitation, 266, 274, 283. See also Wolff-
Parkinson-White syndrome
Pretest probability, of coronary artery disease, 266,
290
obstructive, 268, 268t
Probability analysis, in obstructive coronary artery
disease, 269
Prognosis. See also Risk assessment
Prognostic evaluation, use of exercise testing for
in asymptomatic patients, 290–291
after myocardial infarction, 280
Protocol of exercise test, 264, 265
after myocardial infarction, 283
Pulmonary function, parameters of, 286
Pulmonary stenosis, exercise testing in, in pediatric
patients with, 299t, 300
Pulmonary vascular resistance, elevations of, 298
Q
QRS complex, 265
QT interval
corrected, to exercise, in ventricular arrhythmias
in pediatric patients, 301
long QT syndrome, ventricular tachycardia-
related to, 296
R
R-wave, changes, 273
Regression formula, 286
Regurgitation, valvular
exercise testing for, 293, 294. See also specific
valve
Rehabilitation. See Cardiac rehabilitation
Repolarization
abnormalities, left ventricular hypertrophy with,
272
early, 273
Research on Instability in Coronary artery Disease
(RISC) study group, 279
Respiratory exchange ratio (RER), 286
increase in, 286
Restenosis, after PTCA, exercise testing for, 295t,
295–296
Revascularization, 290
exercise testing before and after, 294–296
exercise testing for obstructive coronary artery
disease after, 267f
Right coronary artery, anomalous, 301
Right ventricular function, abnormalities, 300
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Risk, of exercise testing, 274, 291
in pediatric patients, 297
Risk assessment and prognosis, 263
in patients with symptoms or prior history of
coronary artery disease, 274. See also Risk
stratification
general considerations, 274, 275t
Risk factors, 275
for coronary artery disease
in asymptomatic patients, 291
screening of patients with, 291
modification, 290
Risk stratification
exercise testing for, 293
after myocardial infarction, 282–284
in patients with symptoms or prior history of
coronary artery disease, 275–280
general considerations, 274
Rupture, cardiac, 282
S
Safety, of exercise testing, 264, 265t
after myocardial infarction, 282, 285
Screening
general, 291
of patients with coronary artery disease risk,
291–293
Seattle Heart Watch Study, 291
Sensitivity, of exercise test
in elderly, 289, 289t
from meta-analysis, 271
for obstructive coronary artery disease diagnosis,
268–270
variability of, 270
Shunt, left-to-right, unoperated, exercise testing of
pediatric patients with, 298
Silent defects
graft, 295
ischemia, in elderly, 289
Smoking, 275
Specificity, of exercise test
in elderly, 289, 289t
from meta-analysis, 271
for obstructive coronary artery disease diagnosis,
268–270
variability of, 270
SPECT myocardial imaging, costs and availability
of, 266, 266t
Sports participation, by children with aortic
stenosis, 300
ST-segment
abnormalities, 264, 271
in women, 287, 288
in asymptomatic patients without known
coronary artery disease, 291
changes, during exercise, in children with aortic
stenosis, 300
depression, 265, 268, 298
causes of, 272–273
digoxin-related, 272
downsloping, 272, 273
in elderly, 290
multivariate analysis for diagnosis of
obstructive coronary artery disease and, 302
after myocardial infarction, 282, 283, 285
in obstructive coronary artery disease, 266
at peak exercise, 273
resting, 271, 272, 273, 276
upsloping, 272, 273
deviation, exercise-induced, 278
elevation, 265, 273
false-positive responses, 288
interpretation issues, 273–274
in obstructive coronary artery disease diagnosis,
269
prognostic variables, 276
response criteria, in elderly, 289
resting, depression
studies excluding, 271t
studies including, 270t, 271
in women, 288
Statistical techniques, 276
Stenosis
in elderly, 289
valvular, exercise testing in, 293–294. See also
specific valve
Submaximal protocols, after myocardial infarction,
282
Sudden death, 275, 291
during exercise testing, risk of, 293
Supraventricular arrhythmias during exercise, 296
Surgery
for aortic regurgitation, 294
coronary artery bypass, 280
exercise testing after, 294, 295
postdischarge mortality related to, 282
Symptom(s), pretest probability of coronary artery
disease by, 266, 268t
Symptom-limited testing, 265
after myocardial infarction, 282
event rate, 282
Syncope
exercise testing in, in pediatric patients with,
299t, 300
in tachycardia, 296
T
T-wave, changes, 273
Tachycardia. See also specific type of tachycardia
prolonged, 296
Technical challenges, in exercise testing of pediatric
patients, 298
Termination of exercise testing, indications for,
265, 265t
Tests, choice of, 263
Tetralogy of Fallot, exercise testing in pediatric
patients with, 299t, 300
Thrombolytic therapy, postdischarge mortality
related to, 282
Timing of exercise test, after myocardial infarction,
283
Transposition of great arteries, exercise testing in,
in pediatric patients with, 301–302
Treadmill score
Duke, 277, 278f
intermediate-risk, 278
Treadmill testing, 263, 264, 266, 279
clinical context, 266
costs and availability of, 265, 266t
in elderly, 289
after myocardial infarction, 282
prognosis from, 276
protocols, 264, 265
safety, 286
Treatment
choice of, 263
use of exercise test results in, 280
Tricuspid valve, 298
U
Usefulness of exercise testing, 263
V
Valvular heart disease. See also specific disease;
specific valve
exercise testing in, 293–294
Vco2. See Carbon dioxide outputs
Ventilatory/anaerobic threshold (VAT), 286
determination of, 286–287
Ventilatory gas measurement
data derived from, 287
exercise testing using, 285–287
limitations of, 287
Ventricular arrhythmias, 300
in children and adolescents, 297
exercise testing in, 296
of pediatric patients with, 301
Ventricular function. See Left ventricular function;
Right ventricular function
Ventricular rhythm, paced, 266, 274, 276
Ventricular septal defect, exercise testing in
patients with
in pediatric patients, 299t
Ventricular tachycardia, exercise testing in patients
with, 296
in pediatric patients with, 301
Vo2. See Oxygen, uptake
Volume overload, 294, 298
W
Wolff-Parkinson-White syndrome, 266, 274
Women. See also Gender
cardiovascular disease in, 287, 288
electrocardiographic analysis in, accuracy of,
287–288
exercise testing in
for risk stratification, 278
non-ECG end points in, 288
Work effort, relative, 286
Writing groups, 263
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